{
    "0I1.F": {
        "short_name": "MYHEALTHCHECKED  LS -,001",
        "long_name": "MyHealthChecked Plc",
        "summary": "MyHealthChecked Plc, a women's healthcare company, develops and commercializes mobile health diagnostics medical devices in the United Kingdom. Its products help women with unexplained infertility to concieve. The company offers myLotus, a dual purpose monitoring system that allows both ovulation (LH) and pregnancy (hCG) testing. The company was formerly known as Concepta PLC and changed its name to MyHealthChecked Plc in December 2020. MyHealthChecked Plc was incorporated in 2008 and is based in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF24 5EA",
        "website": "http://myhealthcheckedplc.com",
        "market_cap": "Small Cap"
    },
    "0RX.F": {
        "short_name": "REDX PHARMA  LS -,01",
        "long_name": "Redx Pharma Plc",
        "summary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Macclesfield",
        "zipcode": "SK10 4TG",
        "website": "http://www.redxpharma.com",
        "market_cap": "Small Cap"
    },
    "1JS.F": {
        "short_name": "SHIELD THERAPEUT. LS-,015",
        "long_name": "Shield Therapeutics plc",
        "summary": "Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Gateshead",
        "zipcode": "NE8 3DF",
        "website": "http://www.shieldtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "1M7.F": {
        "short_name": "CAMBR.COGNIT.HLDGS LS-,01",
        "long_name": "Cambridge Cognition Holdings Plc",
        "summary": "Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health solutions in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases I\u00c2\u0096IV or a cognitive testing software that enhances the chances of success and minimizing the risk of failure in neuroscience research; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; and CANTAB Insight, a medical device that helps to determine an individual's cognitive health. In addition, the company offers a range of expert consultancy and operational management services to optimize clinical trials and cognitive research, which include neuroscience and technical consultancy, study design, data analysis, study and data management, and reports and interpretation. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB25 9TU",
        "website": "http://www.cambridgecognition.com",
        "market_cap": "Small Cap"
    },
    "1PK.F": {
        "short_name": "DECHRA PHARMACEUT. LS-,01",
        "long_name": "Dechra Pharmaceuticals PLC",
        "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Northwich",
        "zipcode": "CW9 7UA",
        "website": "http://www.dechra.com",
        "market_cap": "Mid Cap"
    },
    "1RC.SG": {
        "short_name": "Creo Medical Group PLC Register",
        "long_name": "Creo Medical Limited",
        "summary": "Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Speedboat RS2, a medical instrument through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chepstow",
        "zipcode": "NP16 5UH",
        "website": "http://creomedical.com",
        "market_cap": "Small Cap"
    },
    "1RT.F": {
        "short_name": "NUFORMIX PLC  LS -,001",
        "long_name": "Nuformix plc",
        "summary": "Nuformix plc, a pharmaceutical development company, develops drugs using cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP004, which is under the pre-clinical stage for the treatment of multiple forms of fibrosis in various human tissues. It has an agreement with VistaGen Therapeutics, Inc. to develop co-crystal-based formulations of AV-101 for the treatment of various central nervous system conditions. The company also has an option agreement with Oxilio Ltd. to provide consultancy services for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB4 0GN",
        "website": "http://www.nuformix.com",
        "market_cap": "Small Cap"
    },
    "25I.F": {
        "short_name": "IMMUPHARMA PLC  LS-,10",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC1A 7BL",
        "website": "http://www.immupharma.co.uk",
        "market_cap": "Small Cap"
    },
    "2CV.F": {
        "short_name": "CONVATEC GROUP WI LS -,10",
        "long_name": "ConvaTec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urological catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Reading",
        "zipcode": "RG1 3JH",
        "website": "http://www.convatecgroup.com",
        "market_cap": "Mid Cap"
    },
    "2CVU.F": {
        "short_name": "CONVATEC GRP UNSP.ADR /4",
        "long_name": "ConvaTec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urological catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Reading",
        "zipcode": "RG1 3JH",
        "website": "http://www.convatecgroup.com",
        "market_cap": "Mid Cap"
    },
    "2EM.DE": {
        "short_name": "ERGOMED PLC  LS -,01",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "GER",
        "market": "de_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7HJ",
        "website": "http://www.ergomedplc.com",
        "market_cap": "Small Cap"
    },
    "2EM.F": {
        "short_name": "ERGOMED PLC  LS -,01",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7HJ",
        "website": "http://www.ergomedplc.com",
        "market_cap": "Small Cap"
    },
    "2O9.F": {
        "short_name": "RENALYTIX AI PLC LS-,0025",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF64 2EZ",
        "website": "http://www.renalytixai.com",
        "market_cap": "Small Cap"
    },
    "3HY.F": {
        "short_name": "ARIX BIOSCIENCE LS-,00001",
        "long_name": "Arix Bioscience plc",
        "summary": "Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 6JL",
        "website": "http://arixbioscience.com",
        "market_cap": "Small Cap"
    },
    "3WD.F": {
        "short_name": "KANABO GROUP PLC  LS-,025",
        "long_name": "Kanabo Group Plc",
        "summary": "Kanabo Group Plc focuses on the research and development, production, and sale of medical cannabis products to treat CNS disorders. The company intends to offer cannabis-derived products for medical patients; and non-THC products for CBD consumers. It also provides VapePod, a medically certified delivery system for cannabis extracts. The company was founded in 2017 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "NW4 4DJ",
        "website": "http://www.kanabogroup.com",
        "market_cap": "Small Cap"
    },
    "473A.F": {
        "short_name": "ADAPTH.TH.SP.ADR6 LS-,001",
        "long_name": "Adaptimmune Therapeutics plc",
        "summary": "Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Abingdon",
        "zipcode": "OX14 4RX",
        "website": "http://www.adaptimmune.com",
        "market_cap": "Small Cap"
    },
    "4BB.L": {
        "short_name": "4BASEBIO UK SOCIETAS ORD EUR1.0",
        "long_name": "4basebio UK Societas",
        "summary": "4basebio UK Societas develops gene therapy technologies and solutions primarily in the United Kingdom. It focuses on the manufacture and supply of synthetic DNA and non-viral nanoparticles for research, therapeutic, and pharmacological use. The company provides services for biotech and pharma customers in the gene therapy and gene vaccine development. It is also involved in the manufacture of enzymes that are used for diagnostic and laboratory test kits. The company was formerly known as 4Basebio SE and changed its name to 4basebio UK Societas in December 2020. 4basebio UK Societas was incorporated in 2020 and is based in Cambridge, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB24 5QE",
        "website": "http://www.4basebio.com",
        "market_cap": "Small Cap"
    },
    "4KM.SG": {
        "short_name": "Kromek Group PLC Registered Sha",
        "long_name": "Kromek Group plc",
        "summary": "Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection products for medical imaging, nuclear detection, and security screening markets in the United Kingdom, North America, Asia, Europe, and Australasia. Its solutions provide high-resolution information on material composition and structure to enable the identification of cancerous tissues and hazardous materials, as well as for the analysis of radioactive materials. The company also provides a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator technology, such as handheld rugged gamma detectors, thermal neutron detectors, gamma-ray detector spectrometers, scintillator detectors, preamplifiers for radiation detectors and detector electronics, and EV-CPG compact gamma ray detectors, as well as quant GR1 shielded gamma detectors, multichannel analyzers, CZT-based gamma ray imagers, quant air, scalable x-ray CZR linear array, gamma-ray spectroscopy software, gamma ray radionuclide detectors, and voltage to frequency converters. In addition, it offers medical imaging products, including CZT gamma detector for SPECT imaging, CZT bone mineral densitometry detectors, and photon-counting spectral CT. Further, the company provides security products, such as D3 PRD high accuracy, D3M, and D3S PRD personal radiation detectors; D3S wearable RIID gamma neutron detectors; D3S NET networked radiation detectors and static node; static radiation detector; vehicle mounted radiation detectors; UAV radiation mapping drone and AARM system; liquid explosive detection algorithm; and Identifier liquid explosive detectors. Additionally, it engages in scientific research and development activities. The company sells its products through distributors, OEM, and direct sales. Kromek Group plc was incorporated in 2013 and is headquartered in Sedgefield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Sedgefield",
        "zipcode": "TS21 3FD",
        "website": "http://www.kromek.com",
        "market_cap": "Small Cap"
    },
    "4UU.F": {
        "short_name": "DIURNAL GROUP PLC LS -,05",
        "long_name": "Diurnal Group plc",
        "summary": "Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe. It also develops Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF14 4UJ",
        "website": "http://www.diurnal.co.uk",
        "market_cap": "Small Cap"
    },
    "51B.F": {
        "short_name": "BIOVENTIX PLC  LS -,05",
        "long_name": "Bioventix PLC",
        "summary": "Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1W 8DH",
        "website": "http://www.bioventix.com",
        "market_cap": "Small Cap"
    },
    "54I.SG": {
        "short_name": "Instem PLC Registered Shares LS",
        "long_name": "Instem plc",
        "summary": "Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Logbook, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities in non-clinical evaluation studies. In addition, the company provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; SEND Explorer, a web-based application with optional data warehousing capabilities; SENDTrial, a Web based solution that can be accessed through a subscription; and standard for exchange of nonclinical data solutions. Further, it provides Sorcerer Colony Counter for automatic plate counter; anonymization, cloud, validation, and safety assessment and regulatory information management software services; and software solutions to extract intelligence from research and development related healthcare data. Additionally, the company develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Stone",
        "zipcode": "ST15 0SD",
        "website": "http://www.instem.com",
        "market_cap": "Small Cap"
    },
    "5HU.F": {
        "short_name": "HEMOGENYX PHARM.PLC LS-01",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company is developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; CAR-T therapy, a chimeric antigen receptor T-cells for use in immunotherapy, as well as for R/R AML; and Human Postnatal Hemogenic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has a collaboration with GlobalCo. The company was incorporated in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4M 7RD",
        "website": "http://www.hemogenyx.com",
        "market_cap": "Small Cap"
    },
    "5KW.F": {
        "short_name": "SKINBIO THERAP  LS-,01",
        "long_name": "SkinBioTherapeutics Plc",
        "summary": "SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. The company focuses on the development of SkinBiotix technology for use in cosmetic, infection control, and eczema applications. It has an agreement with Croda International Plc for the design and manufacture of a new active cosmetic skincare ingredient based on its SkinBiotix skin microbiome technology; and a research programme with the University of Manchester to investigate and develop microbiome formulations. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Macclesfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Macclesfield",
        "zipcode": "SK11 7QJ",
        "website": "http://www.skinbiotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "5MPA.F": {
        "short_name": "MIDATECH PHARMA LS-,001",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF24 0AA",
        "website": "http://www.midatechpharma.com",
        "market_cap": "Small Cap"
    },
    "5MPD.F": {
        "short_name": "MIDATECH PHARMA SP.ADR/5",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF24 0AA",
        "website": "http://www.midatechpharma.com",
        "market_cap": "Small Cap"
    },
    "5Y6.F": {
        "short_name": "COMPASS PATHW SP.ADR",
        "long_name": "COMPASS Pathways plc",
        "summary": "COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Altrincham",
        "zipcode": "WA14 2DT",
        "website": "http://www.compasspathways.com",
        "market_cap": "Small Cap"
    },
    "63V.F": {
        "short_name": "VERICI DX PLC  LS-,001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Penarth",
        "zipcode": "CF64 2EZ",
        "website": "http://www.vericidx.com",
        "market_cap": "Small Cap"
    },
    "698.MU": {
        "short_name": "ACHILLES THERAP.SP.ADS/1",
        "long_name": "Achilles Therapeutics plc",
        "summary": "Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W6 8PW",
        "website": "http://www.achillestx.com",
        "market_cap": "Small Cap"
    },
    "6A3A.F": {
        "short_name": "AUTOLUS THERAP. SP.ADR/1",
        "long_name": "Autolus Therapeutics plc",
        "summary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W12 7RZ",
        "website": "http://www.autolus.com",
        "market_cap": "Small Cap"
    },
    "6J8.F": {
        "short_name": "SOURCEBIO INTL.  LS-,0015",
        "long_name": "Sourcebio International Plc",
        "summary": "Sourcebio International Plc provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom and internationally. The company's services cover histopathology reporting and human tissue testing services; genomics services to pharmaceuticals, biotechnology, life science, and academic markets; stability storage solutions; and COVID-19 antigen PCR testing services. It also manufactures reagents and kits for the blood group serology, blood banking, and tissue banking sectors; and engages in life science research activities, which cover antibodies, clones, cell culture reagents and assays, protein biology, laboratory essentials, and others. Sourcebio International Plc was incorporated in 2016 and is headquartered in Nottingham, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Nottingham",
        "zipcode": "NG8 6PX",
        "website": "http://www.sourcebioscience.com",
        "market_cap": "Small Cap"
    },
    "6YG.MU": {
        "short_name": "IMMUNOCORE HLDGS ADS/1",
        "long_name": "Immunocore Holdings plc",
        "summary": "Immunocore Holdings plc, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase 3 clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase 1/2 dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase 1/2 dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, SCLC, endometrial, ovarian, and breast cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase 1/2 clinical trial in patients with chronic hepatitis B virus; and IMC-M113V, an ImmTAV product candidate targeting a HIV gag antigen that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Abingdon",
        "zipcode": "OX14 4RY",
        "website": "http://www.immunocore.com",
        "market_cap": "Small Cap"
    },
    "71M.F": {
        "short_name": "MYOVANT SCIENC. DL-,00001",
        "long_name": "Myovant Sciences Ltd.",
        "summary": "Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "SW1Y 4LB",
        "website": "http://myovant.com",
        "market_cap": "Small Cap"
    },
    "78C.F": {
        "short_name": "CLINIGEN GROUP PLC LS-001",
        "long_name": "Clinigen Group plc",
        "summary": "Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Burton-on-Trent",
        "zipcode": "DE14 2WW",
        "website": "http://www.clinigengroup.com",
        "market_cap": "Small Cap"
    },
    "78F.F": {
        "short_name": "FREEL.THERAP.HLD.SP.ADS/1",
        "long_name": "Freeline Therapeutics Holdings plc",
        "summary": "Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Stevenage",
        "zipcode": "SG1 2FX",
        "website": "http://www.freeline.life",
        "market_cap": "Small Cap"
    },
    "7DC.F": {
        "short_name": "DIACEUTICS PLC  LS-,002",
        "long_name": "Diaceutics PLC",
        "summary": "Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and tactical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation; LabEd/workshops, diagnostic adboards, conference support, and proficiency testing services; and Diagnostic reimbursement services. Diaceutics Plc was founded in 2005 and is headquartered in Belfast, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Belfast",
        "zipcode": "BT2 8FE",
        "website": "http://www.diaceutics.com",
        "market_cap": "Small Cap"
    },
    "7HR.F": {
        "short_name": "ZOETIC INT. PLC  LS-,01",
        "long_name": "Zoetic International Plc",
        "summary": "Zoetic International Plc, a vertically integrated CBD company, researches, develops, produces, and sells cannabidiol (CBD) consumer products and other hemp derivatives in the United States and the United Kingdom. The company offers oral CBD tinctures and CBD gummies, as well as softgel, massage oil, and skincare products. Its CBD products are used for pharmaceutical and tobacco replacement applications. The company was formerly known as Highlands Natural Resources plc and changed its name to Zoetic International Plc in September 2019. Zoetic International Plc was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1W 8DH",
        "website": "http://zoeticinternational.com",
        "market_cap": "Small Cap"
    },
    "82C.F": {
        "short_name": "CIRCASSIA GROUP PLC",
        "long_name": "Circassia Group Plc",
        "summary": "Circassia Group Plc, a medical device company, focuses on the respiratory diagnostics and monitoring products. It offers NIOX and NIOX VERO, a fractional exhaled nitric oxide measurement and monitoring products for use in asthma diagnosis and management. The company offers its products through commercial team in the United States, China, the United Kingdom, and Germany, as well as through network of distribution partners internationally. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GA",
        "website": "http://www.circassia.com",
        "market_cap": "Small Cap"
    },
    "8EV.F": {
        "short_name": "EVGEN PHARMA PLC LS-,0025",
        "long_name": "Evgen Pharma plc",
        "summary": "Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Wilmslow",
        "zipcode": "SK9 4LY",
        "website": "http://www.evgen.com",
        "market_cap": "Small Cap"
    },
    "8L7.DU": {
        "short_name": "4BASEBIO UK  EO 1",
        "long_name": "4basebio UK Societas",
        "summary": "4basebio UK Societas develops gene therapy technologies and solutions primarily in the United Kingdom. It focuses on the manufacture and supply of synthetic DNA and non-viral nanoparticles for research, therapeutic, and pharmacological use. The company provides services for biotech and pharma customers in the gene therapy and gene vaccine development. It is also involved in the manufacture of enzymes that are used for diagnostic and laboratory test kits. The company was formerly known as 4Basebio SE and changed its name to 4basebio UK Societas in December 2020. 4basebio UK Societas was incorporated in 2020 and is based in Cambridge, United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "DUS",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB24 5QE",
        "website": "http://www.4basebio.com",
        "market_cap": "Small Cap"
    },
    "90K.F": {
        "short_name": "UMUTHI HEALTH.SOL.LS-,001",
        "long_name": "Umuthi Healthcare Solutions Plc",
        "summary": "Umuthi Healthcare Solutions Plc focuses on the distribution of pharmaceuticals and the provision of medical facilities in remote areas in South Africa. It supplies prescription and other medicines to medical practitioners and health centers. The company was incorporated in 2018 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1W 8DH",
        "website": null,
        "market_cap": null
    },
    "A1V.F": {
        "short_name": "APTORUM GROUP LTD A DL1",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 1BN",
        "website": "http://www.aptorumgroup.com",
        "market_cap": "Small Cap"
    },
    "A8C1.F": {
        "short_name": "ABCAM PLC  LS -,002",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AX",
        "website": "http://www.abcam.com",
        "market_cap": "Mid Cap"
    },
    "A8C3.F": {
        "short_name": "ABCAM PLC SP.ADR 1 LS-002",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AX",
        "website": "http://www.abcam.com",
        "market_cap": "Mid Cap"
    },
    "ABC.L": {
        "short_name": "ABCAM PLC ORD 0.2P",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AX",
        "website": "http://www.abcam.com",
        "market_cap": "Mid Cap"
    },
    "ABCM": {
        "short_name": "Abcam plc",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AX",
        "website": "http://www.abcam.com",
        "market_cap": "Mid Cap"
    },
    "ABCZF": {
        "short_name": "ABCAM PLC",
        "long_name": "Abcam plc",
        "summary": "Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AX",
        "website": "http://www.abcam.com",
        "market_cap": "Mid Cap"
    },
    "ABDX.L": {
        "short_name": "ABINGDON HEALTH PLC ORD 0.025P",
        "long_name": "Abingdon Health Plc",
        "summary": "Abingdon Health Plc, a technology-enabled lateral flow diagnostics company, develops, manufactures, and markets medical diagnostics worldwide. The company offers AbC-19 Rapid Test, a COVID-19 neutralizing antibody test; nucleic acid lateral flow immunoassays; and Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. It also provides lateral flow development, manufacturing, and reader customization services. Additionally, the company provides consultancy services to businesses in the diagnostics sector. Abingdon Health Plc has a collaboration and co-marketing agreement with Abcam plc. The company was founded in 2008 and is headquartered in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "York",
        "zipcode": "YO41 1LZ",
        "website": "http://www.abingdonhealth.com",
        "market_cap": "Small Cap"
    },
    "ABTI": {
        "short_name": "ALTEROLA BIOTECH INC",
        "long_name": "Alterola Biotech, Inc.",
        "summary": "Alterola Biotech, Inc., together with its subsidiaries, focus on the development of cannabinoid, cannabinoid-like, non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), and pharmaceutical medicines made from cannabinoid in United Kingdom and worldwide. The company focuses on developing food-grade ingredients, regulated pharmaceuticals, and regulated food products. In addition, it focuses on the development of bulk ingredients for supply into the cosmetic sector. The company was formerly known as Jedediah Resources Corp. and changed its name to Alterola Biotech, Inc. in July 2010. Alterola Biotech, Inc. was incorporated in 2008 and is based in Birkenhead, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Birkenhead",
        "zipcode": "CH41 5AR",
        "website": "http://www.alterolabiotech.com",
        "market_cap": "Small Cap"
    },
    "ACHL": {
        "short_name": "Achilles Therapeutics plc",
        "long_name": "Achilles Therapeutics plc",
        "summary": "Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W6 8PW",
        "website": "http://www.achillestx.com",
        "market_cap": "Small Cap"
    },
    "ACPH.BR": {
        "short_name": "ACACIA PHARMA",
        "long_name": "Acacia Pharma Group plc",
        "summary": "Acacia Pharma Group plc, a hospital pharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, other invasive procedures, or cancer chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an ultra-short-acting and reversible intravenous sedative benzodiazepine for the use in invasive medical procedures, such as bronchoscopies and colonoscopies; and APD403, an intravenous and oral amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. The company's products are primarily serves anesthesiologists and oncologists. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB22 4QH",
        "website": "http://www.acaciapharma.com",
        "market_cap": "Small Cap"
    },
    "ADAP": {
        "short_name": "Adaptimmune Therapeutics plc",
        "long_name": "Adaptimmune Therapeutics plc",
        "summary": "Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Abingdon",
        "zipcode": "OX14 4RX",
        "website": "http://www.adaptimmune.com",
        "market_cap": "Small Cap"
    },
    "AGL.L": {
        "short_name": "ANGLE PLC ORD 10P",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7AF",
        "website": "http://www.angleplc.com",
        "market_cap": "Small Cap"
    },
    "AGY.L": {
        "short_name": "ALLERGY THERAPEUTICS PLC ORD 0.",
        "long_name": "Allergy Therapeutics plc",
        "summary": "Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Worthing",
        "zipcode": "BN14 8SA",
        "website": "http://www.allergytherapeutics.com",
        "market_cap": "Small Cap"
    },
    "AGYTF": {
        "short_name": "ALLERGY THERAPEUTICS",
        "long_name": "Allergy Therapeutics plc",
        "summary": "Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Worthing",
        "zipcode": "BN14 8SA",
        "website": "http://www.allergytherapeutics.com",
        "market_cap": "Large Cap"
    },
    "AKTX": {
        "short_name": "Akari Therapeutics Plc",
        "long_name": "Akari Therapeutics, Plc",
        "summary": "Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barr\u00c3\u00a9 syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1G 9RT",
        "website": "http://www.akaritx.com",
        "market_cap": "Small Cap"
    },
    "ALIMM.BR": {
        "short_name": "IMMUPHARMA",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "BRU",
        "market": "be_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC1A 7BL",
        "website": "http://www.immupharma.co.uk",
        "market_cap": "Small Cap"
    },
    "ALNOV.PA": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Camberley",
        "zipcode": "GU15 3AD",
        "website": "http://www.novacyt.com",
        "market_cap": "Small Cap"
    },
    "AMS.L": {
        "short_name": "ADVANCED MEDICAL SOLUTIONS GROU",
        "long_name": "Advanced Medical Solutions Group plc",
        "summary": "Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, Europe, the United States, and internationally. It operates in two segments, Surgical and Woundcare. The Surgical segment offers topical tissue adhesives for wound closure and sealing under the LiquiBand; sutures and collagen based products for the surgical and dental markets under the RESORBA; collagens; and laparoscopic device which reduces surgical complications under the LiquiBand Fix8 brands. The Woundcare segment provides wound care platform technologies, which include alginates, foams, films, fibres, hydrogels, antimicrobial dressings, and hydrocolloids, as well as wound care products under the ActivHeal. It also sells its products under the Seal-G and Biomatlante brand names, such as Moldable Bone Graft Substitute, a biphasic calcium phosphate synthetic bone graft substitute that includes Syringes, Inserts, and In'Oss; EZ Cure, a collagen membranes; and Osteotwin, a Biocompatible Interference Resorbable Screw. The company was founded in 1991 and is headquartered in Winsford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Winsford",
        "zipcode": "CW7 3RT",
        "website": "http://www.admedsol.com",
        "market_cap": "Small Cap"
    },
    "ANCR.L": {
        "short_name": "ANIMALCARE GROUP PLC ORD 20P",
        "long_name": "Animalcare Group plc",
        "summary": "Animalcare Group plc engages in the development, sale, and distribution of licensed veterinary pharmaceuticals; and identification of products and services to companion animal veterinary markets in Spain, Portugal, Germany, Italy, other European Union, Asia, the Middle East, Africa, the United Kingdom, Belgium, the Netherlands, and internationally. It is also involved in the marketing of veterinary pharmaceuticals. Animalcare Group plc was founded in 1972 and is based in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "York",
        "zipcode": "YO26 6RB",
        "website": "http://www.animalcaregroup.co.uk",
        "market_cap": "Small Cap"
    },
    "ANPCY": {
        "short_name": "ANGLE",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7AF",
        "website": "http://www.angleplc.com",
        "market_cap": "Small Cap"
    },
    "AOHA.F": {
        "short_name": "RUA LIFE SCIENCES  LS0,05",
        "long_name": "Rua Life Sciences Plc",
        "summary": "Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to Rua Life Sciences Plc in June 2020. Rua Life Sciences Plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Irvine",
        "zipcode": "KA11 5AN",
        "website": "http://www.rualifesciences.com",
        "market_cap": "Small Cap"
    },
    "APH.L": {
        "short_name": "ALLIANCE PHARMA PLC ORD 1P",
        "long_name": "Alliance Pharma plc",
        "summary": "Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It owns or licenses the rights to approximately 80 pharmaceutical and consumer healthcare products. The company also offers medical devices, food supplements, and cosmetics. In addition, the company provides its products under the Kelo-Cote, Nizoral, MacuShield, Vamousse, Flamma Franchise, Aloclair, Hydromol, Forceval, Optiflo, Oxyplastine, Ashton & Parsons, and Ametop brand names. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chippenham",
        "zipcode": "SN15 2BB",
        "website": "http://www.alliancepharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "APM": {
        "short_name": "Aptorum Group Limited",
        "long_name": "Aptorum Group Limited",
        "summary": "Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. Its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 1BN",
        "website": "http://www.aptorumgroup.com",
        "market_cap": "Small Cap"
    },
    "AQA.F": {
        "short_name": "ADVANCED MED.SO.GRP LS-05",
        "long_name": "Advanced Medical Solutions Group plc",
        "summary": "Advanced Medical Solutions Group plc, together with its subsidiaries, designs, develops, manufactures, and distributes products for the wound care, surgical, and wound closure markets in the United Kingdom, Germany, Europe, the United States, and internationally. It operates in two segments, Surgical and Woundcare. The Surgical segment offers topical tissue adhesives for wound closure and sealing under the LiquiBand; sutures and collagen based products for the surgical and dental markets under the RESORBA; collagens; and laparoscopic device which reduces surgical complications under the LiquiBand Fix8 brands. The Woundcare segment provides wound care platform technologies, which include alginates, foams, films, fibres, hydrogels, antimicrobial dressings, and hydrocolloids, as well as wound care products under the ActivHeal. It also sells its products under the Seal-G and Biomatlante brand names, such as Moldable Bone Graft Substitute, a biphasic calcium phosphate synthetic bone graft substitute that includes Syringes, Inserts, and In'Oss; EZ Cure, a collagen membranes; and Osteotwin, a Biocompatible Interference Resorbable Screw. The company was founded in 1991 and is headquartered in Winsford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Winsford",
        "zipcode": "CW7 3RT",
        "website": "http://www.admedsol.com",
        "market_cap": "Small Cap"
    },
    "ARIX.L": {
        "short_name": "ARIX BIOSCIENCE PLC ORD 0.001P",
        "long_name": "Arix Bioscience plc",
        "summary": "Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 6JL",
        "website": "http://arixbioscience.com",
        "market_cap": "Small Cap"
    },
    "AUTL": {
        "short_name": "Autolus Therapeutics plc",
        "long_name": "Autolus Therapeutics plc",
        "summary": "Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W12 7RZ",
        "website": "http://www.autolus.com",
        "market_cap": "Small Cap"
    },
    "AVCT.L": {
        "short_name": "AVACTA GROUP PLC ORD 10P",
        "long_name": "Avacta Group Plc",
        "summary": "Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Wetherby",
        "zipcode": "LS23 7FA",
        "website": "http://www.avacta.com",
        "market_cap": "Small Cap"
    },
    "AVO.L": {
        "short_name": "ADVANCED ONCOTHERAPY PLC ORD 25",
        "long_name": "Advanced Oncotherapy plc",
        "summary": "Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 1TE",
        "website": "http://www.avoplc.com",
        "market_cap": "Small Cap"
    },
    "AZN.BA": {
        "short_name": "ASTRAZENECA",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "ARS",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "BUE",
        "market": "ar_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "AZN.L": {
        "short_name": "ASTRAZENECA PLC ORD SHS $0.25",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; and Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "AZN": {
        "short_name": "Astrazeneca PLC",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; and Alchemab to enhance prostate cancer research. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "AZN.ST": {
        "short_name": "AstraZeneca PLC",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "SEK",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "STO",
        "market": "se_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "AZNCF": {
        "short_name": "ASTRAZENECA",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "AZNN.MX": {
        "short_name": "ASTRAZENECA",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "BCYC": {
        "short_name": "Bicycle Therapeutics plc",
        "long_name": "Bicycle Therapeutics plc",
        "summary": "Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB22 3AT",
        "website": "http://www.bicycletherapeutics.com",
        "market_cap": "Small Cap"
    },
    "BMK.L": {
        "short_name": "BENCHMARK HOLDINGS PLC ORD 0.1P",
        "long_name": "Benchmark Holdings plc",
        "summary": "Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that support the development of food and farming industries worldwide. The company operates through Genetics, Advanced Nutrition, and Health segments. The Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide a range of genetic merit ova. The Advanced Nutrition segment manufactures and offers nutrition and health products to the aquaculture industry. The Health segment provides health products to aquaculture market. Benchmark Holdings plc was founded in 2000 and is based in Sheffield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Sheffield",
        "zipcode": "S35 1QN",
        "website": "http://www.benchmarkplc.com",
        "market_cap": "Small Cap"
    },
    "BQB1.F": {
        "short_name": "YOURGENE HEALTH  LS 0,001",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Manchester",
        "zipcode": "M13 9NQ",
        "website": "http://www.yourgene-health.com",
        "market_cap": "Small Cap"
    },
    "BVXP.L": {
        "short_name": "BIOVENTIX PLC ORD 5P",
        "long_name": "Bioventix PLC",
        "summary": "Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1W 8DH",
        "website": "http://www.bioventix.com",
        "market_cap": "Small Cap"
    },
    "C4J.F": {
        "short_name": "C4X DISCOVERY HLDG.LS-,01",
        "long_name": "C4X Discovery Holdings plc",
        "summary": "C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. It has a suite of proprietary technologies across the drug discovery process, including Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing and designing 4D molecules in virtual reality. The company's product pipeline comprises Oral Orexin-1, an antagonist for the treatment of substance abuse disorders; Oral NRF-2 activators, IL-17 inhibitors, and a4\u00c3\u009f7 integrin inhibitors for the treatment of inflammatory diseases; MALT-1 inhibitors for the treatment of hematological cancer; synthetic lethal novel targets for the treatment of colorectal and lung cancer; and various products for the treatment of neurodegenerative diseases. It has research collaboration agreements with the University of Bristol, the University of Reading, the University of Oxford, and the University of Manchester; and drug discovery partnerships with Indivior PLC, LifeArc, GTN LTD, PhoreMost, e-therapeutics plc, AstraZeneca UK Limited, Evotec, SGC-Oxford, and Horizon Discovery Ltd. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was founded in 2007 and is based in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Manchester",
        "zipcode": "M1 3LD",
        "website": "http://www.c4xdiscovery.com",
        "market_cap": "Small Cap"
    },
    "C4XD.L": {
        "short_name": "C4X DISCOVERY HOLDINGS PLC ORD ",
        "long_name": "C4X Discovery Holdings plc",
        "summary": "C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. It has a suite of proprietary technologies across the drug discovery process, including Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing and designing 4D molecules in virtual reality. The company's product pipeline comprises Oral Orexin-1, an antagonist for the treatment of substance abuse disorders; Oral NRF-2 activators, IL-17 inhibitors, and a4\u00c3\u009f7 integrin inhibitors for the treatment of inflammatory diseases; MALT-1 inhibitors for the treatment of hematological cancer; synthetic lethal novel targets for the treatment of colorectal and lung cancer; and various products for the treatment of neurodegenerative diseases. It has research collaboration agreements with the University of Bristol, the University of Reading, the University of Oxford, and the University of Manchester; and drug discovery partnerships with Indivior PLC, LifeArc, GTN LTD, PhoreMost, e-therapeutics plc, AstraZeneca UK Limited, Evotec, SGC-Oxford, and Horizon Discovery Ltd. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was founded in 2007 and is based in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Manchester",
        "zipcode": "M1 3LD",
        "website": "http://www.c4xdiscovery.com",
        "market_cap": "Small Cap"
    },
    "C5P.F": {
        "short_name": "CARETECH HLDGS  LS -,005",
        "long_name": "CareTech Holdings PLC",
        "summary": "CareTech Holdings PLC provides social care and support services for children and adults in the United Kingdom. It operates in three segments: Adults Services, Children's Services, and Foster Care. The Adult Services segment provides care and residential services for adults with learning disabilities, autistic spectrum and mental health disorders, physical disabilities, and brain injury. The Children's Services segment offers assessment, residential care, and education services for young people with challenging behaviors, and behavioral and emotional disorders. The Foster Care segment provides mainstream and specialist foster care services for children with disabilities in small supportive groups across England and Wales. CareTech Holdings PLC was founded in 1993 and is headquartered in Potters Bar, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Potters Bar",
        "zipcode": "EN6 1AG",
        "website": "http://www.caretech-uk.com",
        "market_cap": "Small Cap"
    },
    "CBX.L": {
        "short_name": "CELLULAR GOODS PLC ORD GBP0.001",
        "long_name": "Cellular Goods PLC",
        "summary": "Cellular Goods PLC manufactures and sells biosynthetic cannabinoids-based consumer products in the United Kingdom. The company provides cannabinoid solutions for skin, movement, and daily living. It offers its products through retailers; direct to consumers through its website; and online. The company was formerly known as Leaf Studios PLC and changed its name to Cellular Goods PLC in September 2020. Cellular Goods PLC was incorporated in 2018 and is based in London, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "WC2B 5DG",
        "website": "http://www.cellulargoods.co",
        "market_cap": "Small Cap"
    },
    "CIR.L": {
        "short_name": "CIRCASSIA GROUP PLC ORD 0.08P",
        "long_name": "Circassia Group Plc",
        "summary": "Circassia Group Plc, a medical device company, focuses on the respiratory diagnostics and monitoring products. It offers NIOX and NIOX VERO, a fractional exhaled nitric oxide measurement and monitoring products for use in asthma diagnosis and management. The company offers its products through commercial team in the United States, China, the United Kingdom, and Germany, as well as through network of distribution partners internationally. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GA",
        "website": "http://www.circassia.com",
        "market_cap": "Small Cap"
    },
    "CLIN.L": {
        "short_name": "CLINIGEN GROUP PLC ORD 0.1P",
        "long_name": "Clinigen Group plc",
        "summary": "Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Burton-on-Trent",
        "zipcode": "DE14 2WW",
        "website": "http://www.clinigengroup.com",
        "market_cap": "Small Cap"
    },
    "CMPS": {
        "short_name": "COMPASS Pathways Plc - American",
        "long_name": "COMPASS Pathways plc",
        "summary": "COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Altrincham",
        "zipcode": "WA14 2DT",
        "website": "http://www.compasspathways.com",
        "market_cap": "Small Cap"
    },
    "CNTA": {
        "short_name": "Centessa Pharmaceuticals plc",
        "long_name": "Centessa Pharmaceuticals Limited",
        "summary": "Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB22 3FH",
        "website": "http://www.centessa.com",
        "market_cap": "Small Cap"
    },
    "CNVVY": {
        "short_name": "CONVATEC GROUP PLC",
        "long_name": "ConvaTec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urological catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Reading",
        "zipcode": "RG1 3JH",
        "website": "http://www.convatecgroup.com",
        "market_cap": "Mid Cap"
    },
    "COG.L": {
        "short_name": "CAMBRIDGE COGNITION HOLDINGS PL",
        "long_name": "Cambridge Cognition Holdings Plc",
        "summary": "Cambridge Cognition Holdings Plc, a neuroscience technology company, develops digital health solutions in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB Recruit, an online patient recruitment platform for pharmaceutical and biotechnology companies to identify qualified clinical trial participants in high-need indications, such as Alzheimer's disease; CANTAB Connect that provides digital cognitive assessment solutions for pharmaceutical clinical trials in various therapeutic areas from Phases I\u00c2\u0096IV or a cognitive testing software that enhances the chances of success and minimizing the risk of failure in neuroscience research; and Cognition Kit, a digital health platform, which delivers wearable and smartphone apps for data collection to provide engaging digital health solutions for the enhancement of patient engagement, demonstration of treatment efficacy, and understanding of a disease and a patient's response to medication. It also provides CANTAB Connect Research, a research software that offers sensitive digital measures of cognitive function for various areas of brain research; CANTAB Mobile, a touchscreen memory test used in clinical research of Alzheimer's disease; CANTAB BrainHealth, an online digital health assessment tool to measure and monitor mental wellbeing and cognitive performance in the workplace; and CANTAB Insight, a medical device that helps to determine an individual's cognitive health. In addition, the company offers a range of expert consultancy and operational management services to optimize clinical trials and cognitive research, which include neuroscience and technical consultancy, study design, data analysis, study and data management, and reports and interpretation. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB25 9TU",
        "website": "http://www.cambridgecognition.com",
        "market_cap": "Small Cap"
    },
    "CREO.L": {
        "short_name": "CREO MEDICAL GROUP PLC ORD GBP0",
        "long_name": "Creo Medical Limited",
        "summary": "Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Speedboat RS2, a medical instrument through a combination of bipolar radiofrequency and microwave energy in a single platform for tissue dissection, resection, ablation, and coagulation. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was founded in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chepstow",
        "zipcode": "NP16 5UH",
        "website": "http://creomedical.com",
        "market_cap": "Small Cap"
    },
    "CRO.F": {
        "short_name": "OPEN ORPHAN PLC  LS-,001",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to Big Pharma, biotech, government, and public health organizations. The company has a portfolio of eight human challenge study models for conditions, such as RSV, flu, asthma and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "E1 8DE",
        "website": "http://www.openorphan.com",
        "market_cap": "Small Cap"
    },
    "CRW.L": {
        "short_name": "CRANEWARE PLC ORD 1P",
        "long_name": "Craneware plc",
        "summary": "Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Toolkit, an automated software-as-a-service (SaaS) chargemaster management solution for capturing optimal legitimate reimbursement for providers; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Reference Plus, a SaaS solution to perform chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; interface scripting module, a software that automatically uploads chargemaster changes to the patient billing system for accurate billing; Trisus Pricing Analyzer, a SaaS solution that simplifies the price modelling process; and Online Reference Toolkit and supplies assistant solutions. It also offers InSight Medical Necessity, a SaaS solution that provides medical necessity validation for the United States payors and advance beneficiary notice creation; Trisus Claims Informatics, a software that automates claim and coding reviews; and InSight Audit, a web-based audit management application for healthcare organizations to manage government and commercial audits. In addition, the company provides Trisus Healthcare Intelligence, a cost analytics and resource efficiency platform; Patient Charge Estimator to simplify the process of providing patient bill estimates for inpatient and outpatient services; InSight Denials to analyze, track, trend, and report on denial data; and appeals services. Further, it offers consulting and professional services; and sales and marketing, product development, and software development services. Craneware plc was founded in 1999 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Edinburgh",
        "zipcode": "EH3 5DA",
        "website": "http://public.craneware.com",
        "market_cap": "Small Cap"
    },
    "CTEC.L": {
        "short_name": "CONVATEC GROUP PLC ORD 10P",
        "long_name": "ConvaTec Group Plc",
        "summary": "ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urological catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products use in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to the manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospitals and the home healthcare sector. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Reading",
        "zipcode": "RG1 3JH",
        "website": "http://www.convatecgroup.com",
        "market_cap": "Mid Cap"
    },
    "CTH.L": {
        "short_name": "CARETECH HOLDINGS PLC ORD 0.5P",
        "long_name": "CareTech Holdings PLC",
        "summary": "CareTech Holdings PLC provides social care and support services for children and adults in the United Kingdom. It operates in three segments: Adults Services, Children's Services, and Foster Care. The Adult Services segment provides care and residential services for adults with learning disabilities, autistic spectrum and mental health disorders, physical disabilities, and brain injury. The Children's Services segment offers assessment, residential care, and education services for young people with challenging behaviors, and behavioral and emotional disorders. The Foster Care segment provides mainstream and specialist foster care services for children with disabilities in small supportive groups across England and Wales. CareTech Holdings PLC was founded in 1993 and is headquartered in Potters Bar, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Potters Bar",
        "zipcode": "EN6 1AG",
        "website": "http://www.caretech-uk.com",
        "market_cap": "Small Cap"
    },
    "CXRXF": {
        "short_name": "ADVANZ PHARMA CORP LTD (JY)",
        "long_name": "ADVANZ PHARMA Corp. Limited",
        "summary": "ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4N 7BL",
        "website": "http://www.advanzpharma.com",
        "market_cap": "Small Cap"
    },
    "D6M.F": {
        "short_name": "GENEDRIVE PLC  LS -,015",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Manchester",
        "zipcode": "M13 9XX",
        "website": "http://www.genedriveplc.com",
        "market_cap": "Small Cap"
    },
    "D89.F": {
        "short_name": "DESTINY PHARMA PLC  LS-01",
        "long_name": "Destiny Pharma plc",
        "summary": "Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops XF-70 for ventilator associated pneumonia/cystic fibrosis/bronchiectasis; DPD-207 for eye infections caused by bacteria and fungi; and XF drugs for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. The company has a collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel antimicrobial candidates from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brighton",
        "zipcode": "BN1 9SB",
        "website": "http://www.destinypharma.com",
        "market_cap": "Small Cap"
    },
    "DDDD.L": {
        "short_name": "4D PHARMA PLC ORD 0.25P",
        "long_name": "4D pharma plc",
        "summary": "4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Leeds",
        "zipcode": "LS1 2JZ",
        "website": "http://www.4dpharmaplc.com",
        "market_cap": "Small Cap"
    },
    "DEMG.L": {
        "short_name": "DELTEX MEDICAL GROUP PLC ORD 1P",
        "long_name": "Deltex Medical Group plc",
        "summary": "Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers Doppler Probes that is used to measure a patient's blood flow and fluid status directly from the descending aorta during surgery and critical care; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure wave algorithm for deriving haemodynamic parameters. The company's products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chichester",
        "zipcode": "PO19 8TX",
        "website": "http://www.deltexmedical.com",
        "market_cap": "Small Cap"
    },
    "DEST.L": {
        "short_name": "DESTINY PHARMA PLC ORD GBP0.01",
        "long_name": "Destiny Pharma plc",
        "summary": "Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops XF-70 for ventilator associated pneumonia/cystic fibrosis/bronchiectasis; DPD-207 for eye infections caused by bacteria and fungi; and XF drugs for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. The company has a collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel antimicrobial candidates from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brighton",
        "zipcode": "BN1 9SB",
        "website": "http://www.destinypharma.com",
        "market_cap": "Small Cap"
    },
    "DNL.L": {
        "short_name": "DIURNAL GROUP PLC ORD GBP0.05",
        "long_name": "Diurnal Group plc",
        "summary": "Diurnal Group plc operates as a specialty pharma company worldwide. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. The company offers Alkindi, a replacement therapy for paediatric adrenal insufficiency in Europe. It also develops Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia and adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF14 4UJ",
        "website": "http://www.diurnal.co.uk",
        "market_cap": "Small Cap"
    },
    "DOC.AX": {
        "short_name": "DOCTORCARE CDI 1:1",
        "long_name": "Doctor Care Anywhere Group PLC",
        "summary": "Doctor Care Anywhere Group PLC operates as a telehealth company in the United Kingdom. It offers services in the areas of appointments, patient records, prescriptions, referrals and fit notes, service improvements, and virtual GP consultations in the form of video and phone. The company provides treatments for allergies, bites and stings, cold and flu, headaches and migraines, joint pains, lifestyle support, mental and sexual health, skin conditions, and stomach and digestive problems, as well as offers internet hospital services in the areas of cardiology, ear, nose and throat, gastroenterology, gynecology, orthopedics, spinal, and urology. It serves medical insurers, employers, retailers, healthcare providers, corporate clients, and private individuals. The company was incorporated in 2013 and is headquartered in London, United Kingdom.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4Y 8DP",
        "website": "http://www.doctorcareanywhere.com",
        "market_cap": "Small Cap"
    },
    "DPH.L": {
        "short_name": "DECHRA PHARMACEUTICALS PLC ORD ",
        "long_name": "Dechra Pharmaceuticals PLC",
        "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Northwich",
        "zipcode": "CW9 7UA",
        "website": "http://www.dechra.com",
        "market_cap": "Mid Cap"
    },
    "DPHN.MX": {
        "short_name": "DECHRA PHARMACEUTICALS",
        "long_name": "Dechra Pharmaceuticals PLC",
        "summary": "Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Major",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Northwich",
        "zipcode": "CW9 7UA",
        "website": "http://www.dechra.com",
        "market_cap": null
    },
    "DSH.F": {
        "short_name": "SENSYNE HEALTH LT  LS-,1",
        "long_name": "Sensyne Health plc",
        "summary": "Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for coronavirus self-monitoring; DBm-Health, which helps individuals monitor their blood glucose levels and share their readings with health care professionals; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include SEND, an early warning system for monitoring patient vital signs in hospital; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. Sensyne Health has strategic research alliance with Bayer to develop new treatments using clinical artificial intelligence; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Milton Keynes University Hospital NHS Foundation Trust to enable the ethical application of clinical artificial intelligence research to improve patient care and research into new medicines; collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Hampshire Hospitals NHS Foundation Trust. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GE",
        "website": "http://www.sensynehealth.com",
        "market_cap": "Small Cap"
    },
    "DVL.F": {
        "short_name": "ALLIANCE PHARMA  LS-,01",
        "long_name": "Alliance Pharma plc",
        "summary": "Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It owns or licenses the rights to approximately 80 pharmaceutical and consumer healthcare products. The company also offers medical devices, food supplements, and cosmetics. In addition, the company provides its products under the Kelo-Cote, Nizoral, MacuShield, Vamousse, Flamma Franchise, Aloclair, Hydromol, Forceval, Optiflo, Oxyplastine, Ashton & Parsons, and Ametop brand names. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chippenham",
        "zipcode": "SN15 2BB",
        "website": "http://www.alliancepharmaceuticals.com",
        "market_cap": "Small Cap"
    },
    "DWV.F": {
        "short_name": "ANGLE PLC  LS-,10",
        "long_name": "ANGLE plc",
        "summary": "ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7AF",
        "website": "http://www.angleplc.com",
        "market_cap": "Small Cap"
    },
    "DXRX.L": {
        "short_name": "DIACEUTICS PLC ORD GBP0.002",
        "long_name": "Diaceutics PLC",
        "summary": "Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic regulation, turnaround time, and sample availability analysis services; diagnostic tracking services, including lab tracking, patient insights, and physician segmentation services; and diagnostic payers research, diagnostic clinical landscape, integrated mapping research, buying process research, and testers/non-testers research services. The company also provides diagnostic planning services consisting of strategic and tactical planning, launch planning, diagnostic partner selection, and financial forecast services; commercialization services comprising content creation; LabEd/workshops, diagnostic adboards, conference support, and proficiency testing services; and Diagnostic reimbursement services. Diaceutics Plc was founded in 2005 and is headquartered in Belfast, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Belfast",
        "zipcode": "BT2 8FE",
        "website": "http://www.diaceutics.com",
        "market_cap": "Small Cap"
    },
    "EAH.L": {
        "short_name": "ECO ANIMAL HEALTH GROUP PLC ORD",
        "long_name": "ECO Animal Health Group plc",
        "summary": "ECO Animal Health Group plc, together with its subsidiaries, develops and markets pharmaceutical products for animals worldwide. The company offers Aivlosin, a macrolide antibiotic for the treatment of respiratory and enteric diseases in pigs and poultry. It also provides generic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic, which are endectocides and other antiparasitics for the treatment and prevention of parasites in cattle, sheep, pigs, horses, and dogs; and Chlortetracycline and Oxytetracycline for treatment of bacterial infections in pigs, poultry, and cattle. The company was founded in 1972 and is headquartered in New Malden, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "New Malden",
        "zipcode": "KT3 4QS",
        "website": "http://www.ecoanimalhealthgroupplc.com",
        "market_cap": "Small Cap"
    },
    "EAJF.F": {
        "short_name": "VALIRX PLC  LS-,001",
        "long_name": "ValiRx plc",
        "summary": "ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression \u00c2\u0096 implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Hatfield",
        "zipcode": "CM22 7BD",
        "website": "http://www.valirx.com",
        "market_cap": "Small Cap"
    },
    "EKF.L": {
        "short_name": "EKF DIAGNOSTICS HOLDINGS PLC OR",
        "long_name": "EKF Diagnostics Holdings plc",
        "summary": "EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, and Africa. It offers DiaSpect and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company offers Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; sTNFRr1, a predictive marker of end stage renal disease; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; Uri-Trak 120 urine analyzer; and RaPET Serology immunoassay kits, as well as reagents, calibrators, standards, and controls. Additionally, it provides contract manufacturing services, as well as services and distributes third party company's products. It sells its products directly to hospitals, laboratories, and government agencies, as well as through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF64 2EZ",
        "website": "http://www.ekfdiagnostics.com",
        "market_cap": "Small Cap"
    },
    "EMIS.L": {
        "short_name": "EMIS GROUP PLC ORD 1P",
        "long_name": "EMIS Group plc",
        "summary": "EMIS Group plc, through its subsidiaries, provides connected healthcare software and systems for healthcare professionals in the United Kingdom. It operates in two segments, EMIS Health and EMIS Enterprise. The EMIS Health segment supplies integrated care technology to national health service markets, including primary, community, acute, and social care. The EMIS Enterprise segment focuses on B2B technology sector in the healthcare market, such as management of medicines, partner businesses, life sciences, and patient-facing services. The company offers clinical software to healthcare organizations under the EMIS brand; patient-centric medical and wellbeing information and digital front door services under the Patient brand name; and service management solutions to the community pharmacy market under the Pinnacle brand. It also operates Patient.info, an online health platform that provides personalized online patient-facing services and healthcare content; Patient Access, which enables people to book appointments; and ProScript and ProScript Connect that enable pharmacies to manage the dispensing process and handle tasks, such as labelling and endorsing, patient records, ordering, and stock control. In addition, the company provides non-clinical ICT solutions for healthcare professionals and other public and private sector organizations; and supplies ICT infrastructure and hosting services. The company was founded in 1987 and is headquartered in Leeds, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Leeds",
        "zipcode": "LS19 6BA",
        "website": "http://www.emisgroupplc.com",
        "market_cap": "Small Cap"
    },
    "EMMLF": {
        "short_name": "OKYO PHARMA LTD",
        "long_name": "OKYO Pharma Limited",
        "summary": "OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 1NA",
        "website": "http://www.okyopharma.com",
        "market_cap": "Small Cap"
    },
    "ERGO.L": {
        "short_name": "ERGOMED PLC ORD 1P",
        "long_name": "Ergomed plc",
        "summary": "Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7HJ",
        "website": "http://www.ergomedplc.com",
        "market_cap": "Small Cap"
    },
    "ETX.L": {
        "short_name": "E-THERAPEUTICS PLC ORD 0.1P",
        "long_name": "e-therapeutics plc",
        "summary": "e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, Novo Nordisk, and Galapagos NV. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Long Hanborough",
        "zipcode": "OX29 8LN",
        "website": "http://www.etherapeutics.co.uk",
        "market_cap": "Small Cap"
    },
    "EVARF": {
        "short_name": "LOMBARD MED INC",
        "long_name": "Lombard Medical, Inc.",
        "summary": "Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, Japan, and internationally. The company's principal product is Aorfix, which is an endovascular stent-graft for the treatment of abdominal aortic aneurysms (AAAs) with angulation at the neck of the aneurysm of up to 90 degrees. Its products also include Altura endovascular stent graft system for the treatment of standard AAA anatomies; Aorflex delivery system for accurate placement of Aorfix in the abdominal aorta; and IntelliFlex LP delivery system that enhances the precision and control of Aorfix deployment and placement. Lombard Medical, Inc. sells its products directly through its direct sales force and distributors to state-or-government-owned hospitals. The company was founded in 2000 and is headquartered in Didcot, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Didcot",
        "zipcode": "OX11 7HJ",
        "website": "http://www.lombardmedical.com",
        "market_cap": "Small Cap"
    },
    "EVG.L": {
        "short_name": "EVGEN PHARMA PLC ORD 0.25P",
        "long_name": "Evgen Pharma plc",
        "summary": "Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Wilmslow",
        "zipcode": "SK9 4LY",
        "website": "http://www.evgen.com",
        "market_cap": "Small Cap"
    },
    "FAB.L": {
        "short_name": "FUSION ANTIBODIES PLC ORD 4P",
        "long_name": "Fusion Antibodies plc",
        "summary": "Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of antibodies, antibody developability, affinity maturation, and antibody reformatting activities. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Belfast",
        "zipcode": "BT17 0QL",
        "website": "http://www.fusionantibodies.com",
        "market_cap": "Small Cap"
    },
    "FDBK.L": {
        "short_name": "FEEDBACK PLC ORD 0.25P",
        "long_name": "Feedback plc",
        "summary": "Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a software tool, which extracts and quantifies texture features in radiological images, assisting research into all tumor types, as well as uncovers biomarkers in medical images; and TexRAD Lung for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, which combines secure instant messaging with the ability to see clinical grade medical images, including X-rays, and CT and MRI scans using portable devices, such as smartphones or tablets. Feedback plc was founded in 1958 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "SE1 7LL",
        "website": "http://fbkmed.com/feedback-plc",
        "market_cap": "Small Cap"
    },
    "FRLN": {
        "short_name": "Freeline Therapeutics Holdings ",
        "long_name": "Freeline Therapeutics Holdings plc",
        "summary": "Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Stevenage",
        "zipcode": "SG1 2FX",
        "website": "http://www.freeline.life",
        "market_cap": "Small Cap"
    },
    "FRPRF": {
        "short_name": "4D PHARMA PLC",
        "long_name": "4D pharma plc",
        "summary": "4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Leeds",
        "zipcode": "LS1 2JZ",
        "website": "http://www.4dpharmaplc.com",
        "market_cap": "Small Cap"
    },
    "FSTX": {
        "short_name": "F-star Therapeutics, Inc.",
        "long_name": "F-star Therapeutics, Inc.",
        "summary": "F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB22 3AT",
        "website": "http://www.f-star.com",
        "market_cap": "Small Cap"
    },
    "FUM.L": {
        "short_name": "FUTURA MEDICAL PLC ORD 0.2P",
        "long_name": "Futura Medical plc",
        "summary": "Futura Medical plc, a pharmaceutical company, researches and develops pharmaceutical drugs and medical devices for the consumer healthcare markets focusing on sexual health and pain relief management. The company offers CSD500, a condom that contains erectogenic gel. It is also developing MED3000, a topical gel for the treatment of erectile dysfunction that has completed Phase III clinical trials. In addition, the company develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7YG",
        "website": "http://www.futuramedical.com",
        "market_cap": "Small Cap"
    },
    "GBE.F": {
        "short_name": "GENUS PLC  LS-,1",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Basingstoke",
        "zipcode": "RG21 4DZ",
        "website": "http://www.genusplc.com",
        "market_cap": "Mid Cap"
    },
    "GDR.L": {
        "short_name": "GENEDRIVE PLC ORD 1.5P",
        "long_name": "genedrive plc",
        "summary": "genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small molecular diagnostic platform, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Manchester",
        "zipcode": "M13 9XX",
        "website": "http://www.genedriveplc.com",
        "market_cap": "Small Cap"
    },
    "GENSF": {
        "short_name": "GENUS",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Basingstoke",
        "zipcode": "RG21 4DZ",
        "website": "http://www.genusplc.com",
        "market_cap": "Mid Cap"
    },
    "GLAXF": {
        "short_name": "GLAXOSMITHKLINE",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brentford",
        "zipcode": "TW8 9GS",
        "website": "http://www.gsk.com",
        "market_cap": "Large Cap"
    },
    "GNS.L": {
        "short_name": "GENUS PLC ORD 10P",
        "long_name": "Genus plc",
        "summary": "Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in vitro fertilization, reproductive, and other technical services to farmers. Genus plc has a strategic porcine collaboration with Beijing Capital Agribusiness Co. Ltd to research, develop, register, and market porcine reproductive and respiratory syndrome virus resistant pigs. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Basingstoke",
        "zipcode": "RG21 4DZ",
        "website": "http://www.genusplc.com",
        "market_cap": "Mid Cap"
    },
    "GS7.DE": {
        "short_name": "GLAXOSMITHKLINE  LS-,25",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brentford",
        "zipcode": "TW8 9GS",
        "website": "http://www.gsk.com",
        "market_cap": "Large Cap"
    },
    "GS7.F": {
        "short_name": "GLAXOSMITHKLINE  LS-,25",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brentford",
        "zipcode": "TW8 9GS",
        "website": "http://www.gsk.com",
        "market_cap": "Large Cap"
    },
    "GS7A.F": {
        "short_name": "GLAXOSMITHKLINE SP. ADR/2",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brentford",
        "zipcode": "TW8 9GS",
        "website": "http://www.gsk.com",
        "market_cap": "Large Cap"
    },
    "GSK.L": {
        "short_name": "GLAXOSMITHKLINE PLC ORD 25P",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brentford",
        "zipcode": "TW8 9GS",
        "website": "http://www.gsk.com",
        "market_cap": "Large Cap"
    },
    "GSK": {
        "short_name": "GlaxoSmithKline PLC",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brentford",
        "zipcode": "TW8 9GS",
        "website": "http://www.gsk.com",
        "market_cap": "Large Cap"
    },
    "GSKN.MX": {
        "short_name": "GLAXOSMITHKLINE",
        "long_name": "GlaxoSmithKline plc",
        "summary": "GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Brentford",
        "zipcode": "TW8 9GS",
        "website": "http://www.gsk.com",
        "market_cap": "Large Cap"
    },
    "GW2A.F": {
        "short_name": "GW PHARMACEUT.SPON.ADR/12",
        "long_name": "GW Pharmaceuticals plc",
        "summary": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB24 9BZ",
        "website": "http://www.gwpharm.com",
        "market_cap": "Mid Cap"
    },
    "GWPH": {
        "short_name": "GW Pharmaceuticals Plc",
        "long_name": "GW Pharmaceuticals plc",
        "summary": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB24 9BZ",
        "website": "http://www.gwpharm.com",
        "market_cap": "Mid Cap"
    },
    "GYX.F": {
        "short_name": "FUTURA MEDICAL  LS-,002",
        "long_name": "Futura Medical plc",
        "summary": "Futura Medical plc, a pharmaceutical company, researches and develops pharmaceutical drugs and medical devices for the consumer healthcare markets focusing on sexual health and pain relief management. The company offers CSD500, a condom that contains erectogenic gel. It is also developing MED3000, a topical gel for the treatment of erectile dysfunction that has completed Phase III clinical trials. In addition, the company develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Guildford",
        "zipcode": "GU2 7YG",
        "website": "http://www.futuramedical.com",
        "market_cap": "Small Cap"
    },
    "H5P.F": {
        "short_name": "HIKMA PHARMACEUTIC.LS-,10",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 2HR",
        "website": "http://www.hikma.com",
        "market_cap": "Mid Cap"
    },
    "HEMO.L": {
        "short_name": "HEMOGENYX PHARMACEUTICALS PLC O",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company is developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; CAR-T therapy, a chimeric antigen receptor T-cells for use in immunotherapy, as well as for R/R AML; and Human Postnatal Hemogenic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has a collaboration with GlobalCo. The company was incorporated in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4M 7RD",
        "website": "http://www.hemogenyx.com",
        "market_cap": "Small Cap"
    },
    "HHI.AX": {
        "short_name": "H HOUSE FPO",
        "long_name": "Health House International Limited",
        "summary": "Health House Holdings Limited engages in the distribution of medicinal cannabis and pharmaceutical products. Health House Holdings Limited was formerly known as CLINICANN LIMITED and changed its name to Health House Holdings Limited in March 2019. The company was founded in 2014 and is based in London, United Kingdom.",
        "currency": "AUD",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "ASX",
        "market": "au_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4A 2DY",
        "website": "http://www.healthhouse.uk",
        "market_cap": null
    },
    "HIK.L": {
        "short_name": "HIKMA PHARMACEUTICALS PLC ORD S",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 2HR",
        "website": "http://www.hikma.com",
        "market_cap": "Mid Cap"
    },
    "HKMPF": {
        "short_name": "HIKMA PHARMACEUTICALS",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 2HR",
        "website": "http://www.hikma.com",
        "market_cap": "Mid Cap"
    },
    "HKMPY": {
        "short_name": "HIKMA PHARMACEUTICALS",
        "long_name": "Hikma Pharmaceuticals PLC",
        "summary": "Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 2HR",
        "website": "http://www.hikma.com",
        "market_cap": "Mid Cap"
    },
    "HOPHF": {
        "short_name": "HEMOGENYX PHARMACEUTICALS PLC",
        "long_name": "Hemogenyx Pharmaceuticals Plc",
        "summary": "Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. The company is developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; CAR-T therapy, a chimeric antigen receptor T-cells for use in immunotherapy, as well as for R/R AML; and Human Postnatal Hemogenic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc has a collaboration with GlobalCo. The company was incorporated in 2013 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4M 7RD",
        "website": "http://www.hemogenyx.com",
        "market_cap": "Small Cap"
    },
    "I9SA.F": {
        "short_name": "VERONA PHARMA SP.ADR 8",
        "long_name": "Verona Pharma plc",
        "summary": "Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "SE1 2RE",
        "website": "http://www.veronapharma.com",
        "market_cap": "Small Cap"
    },
    "IDH.L": {
        "short_name": "IMMUNODIAGNOSTIC SYSTEMS HOLDIN",
        "long_name": "Immunodiagnostic Systems Holdings PLC",
        "summary": "Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Boldon",
        "zipcode": "NE35 9PD",
        "website": "http://www.idsplc.com",
        "market_cap": "Small Cap"
    },
    "IHC.L": {
        "short_name": "INSPIRATION HEALTHCARE GROUP PL",
        "long_name": "Inspiration Healthcare Group plc",
        "summary": "Inspiration Healthcare Group plc, together with its subsidiaries, provides medical devices for use in critical care, operating theatre, and home healthcare applications worldwide. The company offers neonatal intensive care products, such as Unique+ CFM, a wireless electroencephalography monitoring device; a nasal continuous positive airway pressure (nCPAP) device for treating infants, as well as a range of breathing circuits under the Inspire nCPAP name; inspiration air/oxygen blenders; and Tecotherm Neo, a servo control device for total body cooling and warming used in initial stabilization of preterm infants. Its neonatal intensive care products also include LifeStart, a neonatal bedside resuscitation unit; and Inspire rPAP, a 2-piece non-invasive system for the initial stabilization and resuscitation of infants. In addition, the company provides adult intensive care products; AlphaCore5, a patient warming system for prevention of inadvertent hypothermia; and CosyTherm2, a patient warming system for management of body temperature in neonates. Inspiration Healthcare Group plc was founded in 1998 and is headquartered in Crawley, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Crawley",
        "zipcode": "RH10 9NE",
        "website": "http://www.inspiration-healthcare.com",
        "market_cap": "Small Cap"
    },
    "IMCR": {
        "short_name": "Immunocore Holdings plc",
        "long_name": "Immunocore Holdings plc",
        "summary": "Immunocore Holdings plc, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase 3 clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase 1/2 dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase 1/2 dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, SCLC, endometrial, ovarian, and breast cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase 1/2 clinical trial in patients with chronic hepatitis B virus; and IMC-M113V, an ImmTAV product candidate targeting a HIV gag antigen that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Abingdon",
        "zipcode": "OX14 4RY",
        "website": "http://www.immunocore.com",
        "market_cap": "Small Cap"
    },
    "IMM.L": {
        "short_name": "IMMUPHARMA PLC ORD 10P",
        "long_name": "ImmuPharma plc",
        "summary": "ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity, anti-infectives, metabolism, and cancer. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidate includes IPP-204106, a peptide to modulate angiogenesis with application in cancer and ophthalmology; and BioGlucagon a therapy for low sugar events in diabetes. ImmuPharma plc has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. The company was founded in 1999 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC1A 7BL",
        "website": "http://www.immupharma.co.uk",
        "market_cap": "Small Cap"
    },
    "INHC.L": {
        "short_name": "INDUCTION HEALTHCARE GROUP PLC ",
        "long_name": "Induction Healthcare Group PLC",
        "summary": "Induction Healthcare Group PLC provides software to healthcare professionals in the United Kingdom, rest of Europe, the United States, and internationally. It offers Induction Switch, a communication and sharing platform that enables healthcare professionals to connect and collaborate securely with the people they need within a complex clinical environment; MicroGuide, a platform to create, edit, and publish structured and governance-controlled guidance and policies; Zesty, a digital platform that allows patients to book appointments, read appointment and clinical letters, store a local copy of clinical record, and provide data to care teams remotely; and HealthStream that reads and writes demographic, appointment, and clinical record data. The company was incorporated in 2019 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC3R 8HL",
        "website": "http://www.inductionhealthcare.com",
        "market_cap": "Small Cap"
    },
    "INS.L": {
        "short_name": "INSTEM PLC ORD 10P",
        "long_name": "Instem plc",
        "summary": "Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; BioRails for discovery data management; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; and Cyto Study Manager, a data acquisition and reporting solution. The company also offers computational toxicology products and services; Logbook, a repository for information; Morphit for discovery data visualization; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities in non-clinical evaluation studies. In addition, the company provides Samarind RMS to manage medical product information; submit platform that offers tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; SENDView, an application that simplifies the review of SEND datasets; SEND Explorer, a web-based application with optional data warehousing capabilities; SENDTrial, a Web based solution that can be accessed through a subscription; and standard for exchange of nonclinical data solutions. Further, it provides Sorcerer Colony Counter for automatic plate counter; anonymization, cloud, validation, and safety assessment and regulatory information management software services; and software solutions to extract intelligence from research and development related healthcare data. Additionally, the company develops, manufactures, and supplies software and hardware products for in vitro study data collection and management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Stone",
        "zipcode": "ST15 0SD",
        "website": "http://www.instem.com",
        "market_cap": "Small Cap"
    },
    "IUG.L": {
        "short_name": "INTELLIGENT ULTRASOUND GROUP PL",
        "long_name": "Intelligent Ultrasound Group plc",
        "summary": "Intelligent Ultrasound Group plc, through its subsidiaries, develops, markets, and distributes medical training simulators in the United Kingdom, North America, and internationally. It also develops clinical ultrasound software. The company's clinical AI software products include ScanNav Audit, an AI-based ultrasound software product that provides real-time support for ultrasound practitioners, which performs fetal anomaly scans; ScanNav AutoCapture, an AI-based ultrasound software product that automatically captures images; and ScanNav AnatomyGuide, an AI based ultrasound software product, which can automatically identify and highlight key anatomical structures in a live ultrasound image. Its simulator training platforms, comprises of ScanTrainer, a haptic-based ultrasound simulator for obstetrics and gynaecology training markets; HeartWorks, a manikin-based ultrasound simulator for cardiac and anaesthesiology training markets; and BodyWorks, a manikin-based ultrasound simulators for PoCUS, emergency medicine, critical care, and intensive care training markets. The company was formerly known as MedaPhor Group plc and changed its name to Intelligent Ultrasound Group plc in January 2019. Intelligent Ultrasound Group plc was founded in 2004 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF10 1DY",
        "website": "http://www.intelligentultrasound.com",
        "market_cap": "Small Cap"
    },
    "IXI.L": {
        "short_name": "IXICO PLC ORD 1P",
        "long_name": "IXICO plc",
        "summary": "IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services in the fields of Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, And Progressive Supranuclear Palsy, Spinocerebellar Ataxia, and Friedreich's Ataxia diseases, as well as other movement disorders and dementias; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC1A 9PN",
        "website": "http://www.ixico.com",
        "market_cap": "Small Cap"
    },
    "KMK.L": {
        "short_name": "KROMEK GROUP PLC ORD 1P",
        "long_name": "Kromek Group plc",
        "summary": "Kromek Group plc, together with its subsidiaries, develops, manufactures, and sells radiation detection products for medical imaging, nuclear detection, and security screening markets in the United Kingdom, North America, Asia, Europe, and Australasia. Its solutions provide high-resolution information on material composition and structure to enable the identification of cancerous tissues and hazardous materials, as well as for the analysis of radioactive materials. The company also provides a range of radiation detectors that use cadmium zinc telluride (CZT) or scintillator technology, such as handheld rugged gamma detectors, thermal neutron detectors, gamma-ray detector spectrometers, scintillator detectors, preamplifiers for radiation detectors and detector electronics, and EV-CPG compact gamma ray detectors, as well as quant GR1 shielded gamma detectors, multichannel analyzers, CZT-based gamma ray imagers, quant air, scalable x-ray CZR linear array, gamma-ray spectroscopy software, gamma ray radionuclide detectors, and voltage to frequency converters. In addition, it offers medical imaging products, including CZT gamma detector for SPECT imaging, CZT bone mineral densitometry detectors, and photon-counting spectral CT. Further, the company provides security products, such as D3 PRD high accuracy, D3M, and D3S PRD personal radiation detectors; D3S wearable RIID gamma neutron detectors; D3S NET networked radiation detectors and static node; static radiation detector; vehicle mounted radiation detectors; UAV radiation mapping drone and AARM system; liquid explosive detection algorithm; and Identifier liquid explosive detectors. Additionally, it engages in scientific research and development activities. The company sells its products through distributors, OEM, and direct sales. Kromek Group plc was incorporated in 2013 and is headquartered in Sedgefield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Sedgefield",
        "zipcode": "TS21 3FD",
        "website": "http://www.kromek.com",
        "market_cap": "Small Cap"
    },
    "KNB.L": {
        "short_name": "KANABO GROUP PLC ORD 2.5P",
        "long_name": "Kanabo Group Plc",
        "summary": "Kanabo Group Plc focuses on the research and development, production, and sale of medical cannabis products to treat CNS disorders. The company intends to offer cannabis-derived products for medical patients; and non-THC products for CBD consumers. It also provides VapePod, a medically certified delivery system for cannabis extracts. The company was founded in 2017 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Pharmaceutical Retailers",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "NW4 4DJ",
        "website": "http://www.kanabogroup.com",
        "market_cap": "Small Cap"
    },
    "LBPS": {
        "short_name": "4D pharma plc",
        "long_name": "4D pharma plc",
        "summary": "4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Leeds",
        "zipcode": "LS1 2JZ",
        "website": "http://www.4dpharmaplc.com",
        "market_cap": "Small Cap"
    },
    "LIA.F": {
        "short_name": "LIVANOVA PLC  DL -,01",
        "long_name": "LivaNova PLC",
        "summary": "LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W2 6LG",
        "website": "http://www.livanova.com",
        "market_cap": "Mid Cap"
    },
    "LIVN": {
        "short_name": "LivaNova PLC",
        "long_name": "LivaNova PLC",
        "summary": "LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W2 6LG",
        "website": "http://www.livanova.com",
        "market_cap": "Mid Cap"
    },
    "LRSV": {
        "short_name": "LINK RESERVATIONS INC",
        "long_name": "Link Reservations Inc.",
        "summary": "Link Reservations Inc., through its subsidiary, produces cannabidiol-based (CBD) products primarily for pets in Europe and the United States. It develops and markets hemp-based CBD products for cats, dogs, and horses. The company was formerly known as Vendum Batteries, Inc. and changed its name to Link Reservations Inc. in May 2015. Link Reservations Inc. was incorporated in 2006 and is based in Kington, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Kington",
        "zipcode": "HR5 3DJ",
        "website": "http://www.linkreservationsinc.com",
        "market_cap": "Small Cap"
    },
    "LWX.F": {
        "short_name": "IMMUNODIAGNOSTIC  LS -,02",
        "long_name": "Immunodiagnostic Systems Holdings PLC",
        "summary": "Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Boldon",
        "zipcode": "NE35 9PD",
        "website": "http://www.idsplc.com",
        "market_cap": "Small Cap"
    },
    "LXD1.F": {
        "short_name": "INSPIRATION HEA.GR.LS-,10",
        "long_name": "Inspiration Healthcare Group plc",
        "summary": "Inspiration Healthcare Group plc, together with its subsidiaries, provides medical devices for use in critical care, operating theatre, and home healthcare applications worldwide. The company offers neonatal intensive care products, such as Unique+ CFM, a wireless electroencephalography monitoring device; a nasal continuous positive airway pressure (nCPAP) device for treating infants, as well as a range of breathing circuits under the Inspire nCPAP name; inspiration air/oxygen blenders; and Tecotherm Neo, a servo control device for total body cooling and warming used in initial stabilization of preterm infants. Its neonatal intensive care products also include LifeStart, a neonatal bedside resuscitation unit; and Inspire rPAP, a 2-piece non-invasive system for the initial stabilization and resuscitation of infants. In addition, the company provides adult intensive care products; AlphaCore5, a patient warming system for prevention of inadvertent hypothermia; and CosyTherm2, a patient warming system for management of body temperature in neonates. Inspiration Healthcare Group plc was founded in 1998 and is headquartered in Crawley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Crawley",
        "zipcode": "RH10 9NE",
        "website": "http://www.inspiration-healthcare.com",
        "market_cap": "Small Cap"
    },
    "MAH0.F": {
        "short_name": "MEREO BIOPH. ADR  LS-,003",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1G 0QF",
        "website": "http://www.mereobiopharma.com",
        "market_cap": "Small Cap"
    },
    "MAH0.SG": {
        "short_name": "Mereo Biopharma Group Ltd. Reg.",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1G 0QF",
        "website": "http://www.mereobiopharma.com",
        "market_cap": "Small Cap"
    },
    "MDVI.TA": {
        "short_name": "MEDIVIE THERP-M",
        "long_name": "Medivie Therapeutic Ltd",
        "summary": "Medivie Therapeutic Limited develops and markets dental devices. It offers Laboraide, a dental device that is placed between the woman's lower and upper jaw during birth, which allows the relaxation of the jaw, neck, and head muscles through the flow of oxygen to the muscles. The company also develops modular pacifiers that enables development of mouth structure and prevent future damage to the child's gingival structure and teeth. Its product has applications in the areas of birth, migraines, chronic pains, and improving concentration and cognitive activity. The company markets and distributes its products through a network of distributors, as well as online in the Asia, Latin America, the United States, Europe, and Canada. Medivie Therapeutic Limited was founded in 2012 and is based in Hemel Hempstead, the United Kingdom.",
        "currency": "ILA",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "TLV",
        "market": "il_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Hemel Hempstead",
        "zipcode": "HP2 7BN",
        "website": "http://www.medivie.com",
        "market_cap": "Small Cap"
    },
    "MGP.L": {
        "short_name": "MEDICA GROUP PLC ORD 0.2P",
        "long_name": "Medica Group Plc",
        "summary": "Medica Group Plc provides teleradiology reporting services to NHS trusts, private hospital groups, and diagnostic imaging companies in the United Kingdom. It offers NightHawk emergency computerised tomography (CT) and MR reporting, routine cross sectional, routine plain film, and radiographer plain film services. The company also provides audit services, such as cause for concern audit, departmental quality assurance, and ongoing CT, MR, plain film, and ultrasound audit services; and multiparametric prostate magnetic resonance imaging, specialist cardiac reporting, CT colonoscopy, DXA reporting, nuclear medicine examination, tailored cancer reporting, PET-CT, and CBCT services. Medica Group Plc was incorporated in 2013 and is based in Hastings, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Hastings",
        "zipcode": "TN34 1EA",
        "website": "http://www.medicagroup.co.uk",
        "market_cap": "Small Cap"
    },
    "MHC.L": {
        "short_name": "MYHEALTHCHECKED PLC ORD 0.1P",
        "long_name": "MyHealthChecked Plc",
        "summary": "MyHealthChecked Plc, a women's healthcare company, develops and commercializes mobile health diagnostics medical devices in the United Kingdom. Its products help women with unexplained infertility to concieve. The company offers myLotus, a dual purpose monitoring system that allows both ovulation (LH) and pregnancy (hCG) testing. The company was formerly known as Concepta PLC and changed its name to MyHealthChecked Plc in December 2020. MyHealthChecked Plc was incorporated in 2008 and is based in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF24 5EA",
        "website": "http://myhealthcheckedplc.com",
        "market_cap": "Small Cap"
    },
    "MREO": {
        "short_name": "Mereo BioPharma Group plc",
        "long_name": "Mereo BioPharma Group plc",
        "summary": "Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1G 0QF",
        "website": "http://www.mereobiopharma.com",
        "market_cap": "Small Cap"
    },
    "MTP": {
        "short_name": "Midatech Pharma PLC",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF24 0AA",
        "website": "http://www.midatechpharma.com",
        "market_cap": "Small Cap"
    },
    "MTPH.L": {
        "short_name": "MIDATECH PHARMA PLC ORD 0.1P",
        "long_name": "Midatech Pharma plc",
        "summary": "Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF24 0AA",
        "website": "http://www.midatechpharma.com",
        "market_cap": "Small Cap"
    },
    "MYOV": {
        "short_name": "Myovant Sciences Ltd.",
        "long_name": "Myovant Sciences Ltd.",
        "summary": "Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. As of December 27, 2019, Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "SW1Y 4LB",
        "website": "http://myovant.com",
        "market_cap": "Small Cap"
    },
    "N04A.F": {
        "short_name": "NUCANA  SP.ADR 1/ LS-,04",
        "long_name": "NuCana plc",
        "summary": "NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Edinburgh",
        "zipcode": "EH12 9DT",
        "website": "http://www.nucana.com",
        "market_cap": "Small Cap"
    },
    "N4P.L": {
        "short_name": "N4 PHARMA PLC ORD 0.4P",
        "long_name": "N4 Pharma Plc",
        "summary": "N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. The company has a research collaboration with Nanomerics Limited to focus on the different formulations of Nuvec delivery system. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC3V 0HR",
        "website": "http://www.n4pharma.com",
        "market_cap": "Small Cap"
    },
    "NCNA": {
        "short_name": "NuCana plc",
        "long_name": "NuCana plc",
        "summary": "NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in Phase I clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. NuCana plc has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Edinburgh",
        "zipcode": "EH12 9DT",
        "website": "http://www.nucana.com",
        "market_cap": "Small Cap"
    },
    "NCYT.L": {
        "short_name": "NOVACYT S.A. EUR1/15TH (CDI)",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Camberley",
        "zipcode": "GU15 3AD",
        "website": "http://www.novacyt.com",
        "market_cap": "Small Cap"
    },
    "NFX.L": {
        "short_name": "NUFORMIX PLC ORD 0.1P",
        "long_name": "Nuformix plc",
        "summary": "Nuformix plc, a pharmaceutical development company, develops drugs using cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP004, which is under the pre-clinical stage for the treatment of multiple forms of fibrosis in various human tissues. It has an agreement with VistaGen Therapeutics, Inc. to develop co-crystal-based formulations of AV-101 for the treatment of various central nervous system conditions. The company also has an option agreement with Oxilio Ltd. to provide consultancy services for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB4 0GN",
        "website": "http://www.nuformix.com",
        "market_cap": "Small Cap"
    },
    "NMHLY": {
        "short_name": "NMC HEALTH PLC",
        "long_name": "NMC Health Plc",
        "summary": "NMC Health Plc provides healthcare services in the United Arab Emirates, the United Kingdom, Spain, and internationally. The company operates through two segments, Healthcare, and Distribution & Services. It owns and manages approximately 200 healthcare facilities, including hospitals, medical centers, long term care facilities, day surgery centers, fertility clinics, and home health services providers. The company offers medical services comprising diagnostic, and in and outpatient services, as well as research and medical services in the field of gynecology, obstetrics, and human reproduction; and management services in respect of hospitals, as well as retails pharmaceutical goods. It also trades in pharmaceutical goods, medical equipment, cosmetics, and food products. NMC Health Plc was founded in 1975 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1J 8AJ",
        "website": "http://nmc.ae",
        "market_cap": "Small Cap"
    },
    "NPW1.F": {
        "short_name": "SMITH + NEP.  DL -,20",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Watford",
        "zipcode": "WD18 8YE",
        "website": "http://www.smith-nephew.com",
        "market_cap": "Large Cap"
    },
    "NPWA.F": {
        "short_name": "SMITH+NEPHEW ADR5 DL-20/2",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Watford",
        "zipcode": "WD18 8YE",
        "website": "http://www.smith-nephew.com",
        "market_cap": "Large Cap"
    },
    "NSAV": {
        "short_name": "NET SAVINGS LINK INC",
        "long_name": "Net Savings Link, Inc.",
        "summary": "Net Savings Link, Inc. operates as a cryptocurrency, blockchain, and digital asset technology company. It holds interests in Cryptocurrency Trading Platform based on Artificial Intelligence (AI) and offers a range of trading services, such as portfolio management and price search function. This platform supports various cryptocurrency exchanges. The company is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 4QW",
        "website": null,
        "market_cap": "Small Cap"
    },
    "NSCI.L": {
        "short_name": "NETSCIENTIFIC PLC ORD 5P",
        "long_name": "NetScientific plc",
        "summary": "NetScientific plc is a venture capital firm specializing in seed, early and mid stage investments. The firm focuses to invest in transformative biomedical and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases. Within digital health it focuses on data analytics, wearable technologies, and devices. The firm seeks to invest in companies based in European developed markets and in the United States. It typically invests up to $15 million, but may consider larger amounts. It prefers to hold a controlling interest in all principal subsidiaries. The firm prefers to invest through its balance sheet investments. NetScientific plc was founded in 2008 and is based in London, United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "E14 5AB",
        "website": "http://www.netscientific.net",
        "market_cap": "Small Cap"
    },
    "NVYTF": {
        "short_name": "NOVACYT",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Camberley",
        "zipcode": "GU15 3AD",
        "website": "http://www.novacyt.com",
        "market_cap": "Small Cap"
    },
    "NYZ.F": {
        "short_name": "NOVACYT  EO-,0667",
        "long_name": "Novacyt S.A.",
        "summary": "Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, and commercialization of clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics, and Molecular Products segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Products segment designs, manufactures, and distributes test kits for various diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents and tests for in vitro diagnostic tests and blood grouping applications under the Plasmatec and Biotec brand names. The company has collaboration with AstraZeneca, GSK, and the University of Cambridge to support increase testing for COVID-19. It serves universities, hospitals, clinics, and testing laboratories. Novacyt S.A. was founded in 2006 and is headquartered in Camberley, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Camberley",
        "zipcode": "GU15 3AD",
        "website": "http://www.novacyt.com",
        "market_cap": "Small Cap"
    },
    "NZCA.F": {
        "short_name": "PROVEXIS PLC  LS-,001",
        "long_name": "Provexis plc",
        "summary": "Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Reading",
        "zipcode": "RG1 1AZ",
        "website": "http://www.provexis.org",
        "market_cap": "Small Cap"
    },
    "OB3.F": {
        "short_name": "OPTIBIOTIX HLTH PLC LS-02",
        "long_name": "OptiBiotix Health Plc",
        "summary": "Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that ID used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc has an agreement with Fondazione Edmund Mach - Centro Ricerca e Innovazione to jointly fund and carry out a research project examining the role of its microbiome products to improve sleep, stress, and anxiety. The company was founded in 2012 and is headquartered in York, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "York",
        "zipcode": "YO10 5DG",
        "website": "http://www.optibiotix.com",
        "market_cap": "Small Cap"
    },
    "OBD.L": {
        "short_name": "OXFORD BIODYNAMICS PLC ORD GBP0",
        "long_name": "Oxford BioDynamics Plc",
        "summary": "Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United states and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures. It has collaboration agreements with University of Glasgow for prognostic and predictive profiling of COVID-19 patients in the GETAFIX. Oxford BioDynamics Plc was founded in 2007 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 2JZ",
        "website": "http://www.oxfordbiodynamics.com",
        "market_cap": "Small Cap"
    },
    "OCY.SG": {
        "short_name": "Oncimmune Holdings PLC Register",
        "long_name": "Oncimmune Holdings plc",
        "summary": "Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Nottingham",
        "zipcode": "NG90 6BH",
        "website": "http://www.oncimmune.com",
        "market_cap": "Small Cap"
    },
    "ODX.L": {
        "short_name": "OMEGA DIAGNOSTICS GROUP PLC ORD",
        "long_name": "Omega Diagnostics Group PLC",
        "summary": "Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries, Africa, and the Middle East. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases. This segment's product includes 69 CE-marked allergens. The Food Intolerance segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides CNS laboratory services that offer clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Infectious Diseases and Other segment is involved in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment's products include VISITECT CD4, an in-vitro diagnostic test, which is used in the management of patients with pre-diagnosed HIV infection, as well as develops and manufactures COVID-19 antibody and antigen tests. The company offers its products to hospitals, clinics, and laboratories through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Alva",
        "zipcode": "FK12 5DQ",
        "website": "http://www.omegadiagnostics.com",
        "market_cap": "Small Cap"
    },
    "OKYO.L": {
        "short_name": "OKYO PHARMA LIMITED ORD NPV",
        "long_name": "OKYO Pharma Limited",
        "summary": "OKYO Pharma Limited operates as a life sciences and biopharmaceutical company in the United Kingdom. Its pre-clinical development program includes Chemerin for the treatment of ocular inflammation, dry eye disease, and ocular neuropathic pain; and BAM8, a non-opioid analgesic. OKYO Pharma Limited is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 1NA",
        "website": "http://www.okyopharma.com",
        "market_cap": "Small Cap"
    },
    "OMY.SG": {
        "short_name": "Synairgen PLC Registered Shares",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Southampton",
        "zipcode": "SO16 6YD",
        "website": "http://www.synairgen.com",
        "market_cap": "Small Cap"
    },
    "ONC.L": {
        "short_name": "ONCIMMUNE HOLDINGS PLC ORD 1P",
        "long_name": "Oncimmune Holdings plc",
        "summary": "Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for early detection of lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers that can help stratify patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID disease-specific stratification panels. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Nottingham",
        "zipcode": "NG90 6BH",
        "website": "http://www.oncimmune.com",
        "market_cap": "Small Cap"
    },
    "OPORF": {
        "short_name": "OPEN ORPHAN PLC",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to Big Pharma, biotech, government, and public health organizations. The company has a portfolio of eight human challenge study models for conditions, such as RSV, flu, asthma and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "E1 8DE",
        "website": "http://www.openorphan.com",
        "market_cap": "Small Cap"
    },
    "OPTI.L": {
        "short_name": "OPTIBIOTIX HEALTH PLC ORD 2P",
        "long_name": "OptiBiotix Health Plc",
        "summary": "Optibiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that ID used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; and Sweetbiotix, a sweetener for use in food products and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. Optibiotix Health Plc has an agreement with Fondazione Edmund Mach - Centro Ricerca e Innovazione to jointly fund and carry out a research project examining the role of its microbiome products to improve sleep, stress, and anxiety. The company was founded in 2012 and is headquartered in York, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "York",
        "zipcode": "YO10 5DG",
        "website": "http://www.optibiotix.com",
        "market_cap": "Small Cap"
    },
    "ORPH.IR": {
        "short_name": "OPEN ORPHAN PLC",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to Big Pharma, biotech, government, and public health organizations. The company has a portfolio of eight human challenge study models for conditions, such as RSV, flu, asthma and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "ISE",
        "market": "ie_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "E1 8DE",
        "website": "http://www.openorphan.com",
        "market_cap": "Small Cap"
    },
    "ORPH.L": {
        "short_name": "OPEN ORPHAN PLC ORD 0.1P",
        "long_name": "Open Orphan plc",
        "summary": "Open Orphan plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to Big Pharma, biotech, government, and public health organizations. The company has a portfolio of eight human challenge study models for conditions, such as RSV, flu, asthma and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "E1 8DE",
        "website": "http://www.openorphan.com",
        "market_cap": "Small Cap"
    },
    "ORTX": {
        "short_name": "Orchard Therapeutics plc",
        "long_name": "Orchard Therapeutics plc",
        "summary": "Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4N 6EU",
        "website": "http://www.orchard-tx.com",
        "market_cap": "Small Cap"
    },
    "OT1A.F": {
        "short_name": "ORCHARD THERAP.SP.ADRS/1",
        "long_name": "Orchard Therapeutics plc",
        "summary": "Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4N 6EU",
        "website": "http://www.orchard-tx.com",
        "market_cap": "Small Cap"
    },
    "OXB.L": {
        "short_name": "OXFORD BIOMEDICA PLC ORD 50P",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 6LT",
        "website": "http://www.oxb.com",
        "market_cap": "Small Cap"
    },
    "OXBDF": {
        "short_name": "OXFORD BIOMEDICA",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 6LT",
        "website": "http://www.oxb.com",
        "market_cap": "Small Cap"
    },
    "OXOA.F": {
        "short_name": "OXFORD BIOMEDICA  LS-,50",
        "long_name": "Oxford Biomedica plc",
        "summary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 6LT",
        "website": "http://www.oxb.com",
        "market_cap": "Small Cap"
    },
    "PI2.F": {
        "short_name": "PROTEOME SCIENCES  LS-01",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro; and manufactures small and protein-reactive chemical reagents. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay for multi-protein biomarker panels. It primarily serves pharmaceutical and biotechnology companies, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "WC1H 9BB",
        "website": "http://www.proteomics.com",
        "market_cap": "Small Cap"
    },
    "PLPL": {
        "short_name": "PLANDAI BIOTECHNOLOGY INC",
        "long_name": "Planda\u00ed Biotechnology, Inc.",
        "summary": "Planda\u00c3\u00ad Biotechnology, Inc. focuses on the production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. It is developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested in the Senteeko Tea Estate in Mpumalanga, South Africa; and Phytofare citrus complex, a citrus extract, as well as extracts from tomato fruit, Artemisia, and cannabis. The company also produces and sells timber and agricultural products from its farm and tea estate holdings in South Africa. Planda\u00c3\u00ad Biotechnology, Inc. is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 1BN",
        "website": "http://www.plandaibiotech.com",
        "market_cap": "Small Cap"
    },
    "PMSNF": {
        "short_name": "PROTEOME SCIENCES",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro; and manufactures small and protein-reactive chemical reagents. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay for multi-protein biomarker panels. It primarily serves pharmaceutical and biotechnology companies, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "WC1H 9BB",
        "website": "http://www.proteomics.com",
        "market_cap": "Small Cap"
    },
    "PRM.L": {
        "short_name": "PROTEOME SCIENCES PLC ORD 1P",
        "long_name": "Proteome Sciences plc",
        "summary": "Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company develops the technology for isobaric tandem mass tag (TMT) and TMTpro; and manufactures small and protein-reactive chemical reagents. It offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the most important factor. The company also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay for multi-protein biomarker panels. It primarily serves pharmaceutical and biotechnology companies, including academic research. The company was incorporated in 1993 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "WC1H 9BB",
        "website": "http://www.proteomics.com",
        "market_cap": "Small Cap"
    },
    "PXS.L": {
        "short_name": "PROVEXIS PLC ORD 0.1P",
        "long_name": "Provexis plc",
        "summary": "Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Reading",
        "zipcode": "RG1 1AZ",
        "website": "http://www.provexis.org",
        "market_cap": "Small Cap"
    },
    "PYC.L": {
        "short_name": "PHYSIOMICS PLC ORD 0.4P",
        "long_name": "Physiomics Plc",
        "summary": "Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GA",
        "website": "http://www.physiomics-plc.com",
        "market_cap": "Small Cap"
    },
    "PYPB.F": {
        "short_name": "IXICO PLC  LS -,01",
        "long_name": "IXICO plc",
        "summary": "IXICO plc provides data analytics services to the biopharmaceutical industry in the United States, the United Kingdom, Europe, and internationally. It provides collection, analysis, management, and reporting services on data generated in the course of a clinical study. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services in the fields of Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, And Progressive Supranuclear Palsy, Spinocerebellar Ataxia, and Friedreich's Ataxia diseases, as well as other movement disorders and dementias; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC1A 9PN",
        "website": "http://www.ixico.com",
        "market_cap": "Small Cap"
    },
    "R1V.F": {
        "short_name": "TRISTEL PLC  LS-,01",
        "long_name": "Tristel plc",
        "summary": "Tristel plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products under the Tristel brand; surface cleaning and disinfection products used in areas, such as hospitals, rescue vehicles, care homes, hospices, dentists, and GP surgeries under the Cache brand; contamination control products for pharmaceutical and personal care industries under the Crystel brand; and animal health infection prevention and control products under the Anistel brand. Tristel plc was founded in 1993 and is based in Snailwell, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Snailwell",
        "zipcode": "CB8 7NY",
        "website": "http://www.tristel.com",
        "market_cap": "Small Cap"
    },
    "R3I1.F": {
        "short_name": "ADVANCED ONCOTHER. LS-,25",
        "long_name": "Advanced Oncotherapy plc",
        "summary": "Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1S 1TE",
        "website": "http://www.avoplc.com",
        "market_cap": "Small Cap"
    },
    "RAP.SW": {
        "short_name": "Rapid Nutrition N",
        "long_name": "Rapid Nutrition PLC",
        "summary": "Rapid Nutrition PLC, a natural healthcare company, researches, develops, and produces a range of life science products. The company offers meal replacement shakes, energy boosting tablets, weight loss tablets, and appetite suppressant powders under the Leisa's Secret brand; and high protein shakes, high fiber bars, organic multivitamins, fat burning shots, and grain granola cereals under the SystemLS brand. It primarily exports its products in Asia, Europe, Africa, the Middle East, North America, and Australia. The company was incorporated in 2001 and is based in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "EBS",
        "market": "ch_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "WC1N 3AX",
        "website": "http://www.rnplc.com",
        "market_cap": "Small Cap"
    },
    "REDX.L": {
        "short_name": "REDX PHARMA PLC ORD 1P",
        "long_name": "Redx Pharma Plc",
        "summary": "Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company is developing RXC004, a porcupine inhibitor, which has completed Phase I clinical development for the treatment of colorectal, pancreatic, biliary, and gastric cancers, as well as melanoma; ROCK inhibitor for treating inflammatory intestinal fibrosis; RXC007, a Rho-associated protein kinase 2 inhibitors for the treatment of orphan disease, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, and other systemic fibrotic conditions; and Porcupine (RXC006), which is in Phase I for the treatment of lung fibrosis. Redx Pharma Plc has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. The company was founded in 2010 and is based in Macclesfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Macclesfield",
        "zipcode": "SK10 4TG",
        "website": "http://www.redxpharma.com",
        "market_cap": "Small Cap"
    },
    "RENE.L": {
        "short_name": "RENEURON GROUP PLC ORD 1P",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Pencoed",
        "zipcode": "CF35 5HY",
        "website": "http://www.reneuron.com",
        "market_cap": "Small Cap"
    },
    "RENX.L": {
        "short_name": "RENALYTIX AI PLC ORD 0.25P",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF64 2EZ",
        "website": "http://www.renalytixai.com",
        "market_cap": "Small Cap"
    },
    "RNLX": {
        "short_name": "Renalytix AI plc",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "NGM",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF64 2EZ",
        "website": "http://www.renalytixai.com",
        "market_cap": "Small Cap"
    },
    "RNUGF": {
        "short_name": "RENEURON GROUP",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Pencoed",
        "zipcode": "CF35 5HY",
        "website": "http://www.reneuron.com",
        "market_cap": "Small Cap"
    },
    "ROQ.L": {
        "short_name": "ROQUEFORT INVESTMENTS PLC ORD 1",
        "long_name": "Roquefort Investments plc",
        "summary": "Roquefort Investments plc, an investment company, intends to acquire businesses focused on early-stage opportunities in the medical biotechnology sector. It focuses on drug and vaccine development, diagnostics, immuno-therapy, and cell and gene therapy areas. The company was incorporated in 2020 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "SW1W 9NF",
        "website": "http://www.roquefortinvest.com",
        "market_cap": "Small Cap"
    },
    "RPNRF": {
        "short_name": "RAPID NUTRITION PLC",
        "long_name": "Rapid Nutrition PLC",
        "summary": "Rapid Nutrition PLC, a natural healthcare company, researches, develops, and produces a range of life science products. The company offers meal replacement shakes, energy boosting tablets, weight loss tablets, and appetite suppressant powders under the Leisa's Secret brand; and high protein shakes, high fiber bars, organic multivitamins, fat burning shots, and grain granola cereals under the SystemLS brand. It primarily exports its products in Asia, Europe, Africa, the Middle East, North America, and Australia. The company was incorporated in 2001 and is based in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "WC1N 3AX",
        "website": "http://www.rnplc.com",
        "market_cap": "Small Cap"
    },
    "RQE1.F": {
        "short_name": "RENEURON GRP PLC  LS-,01",
        "long_name": "ReNeuron Group plc",
        "summary": "ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in Phase IIb clinical trial for stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also developing CTX-derived exosomes, which are Nano-sized packages of information released by CTX cells. ReNeuron Group plc has a research agreement with U.S. biotechnology company in the discovery and development of novel gene silencing-based therapeutics. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Pencoed",
        "zipcode": "CF35 5HY",
        "website": "http://www.reneuron.com",
        "market_cap": "Small Cap"
    },
    "RTNXF": {
        "short_name": "RENALYTIX AI PLC",
        "long_name": "Renalytix AI plc",
        "summary": "Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cardiff",
        "zipcode": "CF64 2EZ",
        "website": "http://www.renalytixai.com",
        "market_cap": "Small Cap"
    },
    "RTQ1.F": {
        "short_name": "AVACTA GROUP PLC  LS-,10",
        "long_name": "Avacta Group Plc",
        "summary": "Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnostics, Therapeutics, and Animal Health segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops novel cancer immunotherapies combining proprietary platforms; and provides tools and contract services to assist diagnosis of conditions in animals to enable faster treatment for veterinarians. The company has a research partnership with Moderna Therapeutics; research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein; co-development partnership agreement with Bach Biosciences LLP to develop Affimer drug conjugate therapies; drug development collaboration with LG Chem Life Sciences; a partnership with Selexis to develop cell line for clinical manufacturing, and with Tufts University School of Medicine for developing Affimer drug conjugate therapies; a collaboration with Cytiva to develop and manufacture an Affimer-based point-of-care rapid test; and a collaboration with Adeptrix to develop Affimer-based COVID-19 antigen tests. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Wetherby",
        "zipcode": "LS23 7FA",
        "website": "http://www.avacta.com",
        "market_cap": "Small Cap"
    },
    "RTRA.F": {
        "short_name": "TIZIANA LI.ADR /2 LS-,03",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 1NA",
        "website": "http://www.tizianalifesciences.com",
        "market_cap": "Small Cap"
    },
    "RUA.L": {
        "short_name": "RUA LIFE SCIENCES PLC ORD 5P",
        "long_name": "Rua Life Sciences Plc",
        "summary": "Rua Life Sciences Plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to Rua Life Sciences Plc in June 2020. Rua Life Sciences Plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Irvine",
        "zipcode": "KA11 5AN",
        "website": "http://www.rualifesciences.com",
        "market_cap": "Small Cap"
    },
    "RVKA.F": {
        "short_name": "OMEGA DIAGNOST.GR. LS-,04",
        "long_name": "Omega Diagnostics Group PLC",
        "summary": "Omega Diagnostics Group PLC, through its subsidiaries, develops, manufactures, and distributes medical diagnostics products in the United Kingdom, rest of Europe, North America, South/Central America, India, other Asian countries, Africa, and the Middle East. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Diseases and Other. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in-vitro allergy and autoimmune tests used by doctors to diagnose patients with allergies and autoimmune diseases. This segment's product includes 69 CE-marked allergens. The Food Intolerance segment engages in the research, development, and production of kits to aid the detection of immune reactions to food under the Foodprint name. This segment also provides CNS laboratory services that offer clinical analysis to the general public, clinics, and health professionals, as well as supplies Food Detective, a consumer food test. The Infectious Diseases and Other segment is involved in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases. This segment's products include VISITECT CD4, an in-vitro diagnostic test, which is used in the management of patients with pre-diagnosed HIV infection, as well as develops and manufactures COVID-19 antibody and antigen tests. The company offers its products to hospitals, clinics, and laboratories through distributors in approximately 75 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Alva",
        "zipcode": "FK12 5DQ",
        "website": "http://www.omegadiagnostics.com",
        "market_cap": "Small Cap"
    },
    "RVW1.F": {
        "short_name": "PHYSIOMICS PLC  LS -,004",
        "long_name": "Physiomics Plc",
        "summary": "Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the European Union, and the United States. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GA",
        "website": "http://www.physiomics-plc.com",
        "market_cap": "Small Cap"
    },
    "S00.F": {
        "short_name": "SPIRE HEALTHCARE GRP",
        "long_name": "Spire Healthcare Group plc",
        "summary": "Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, foreign visa medical exams, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory care, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology care, vascular care, weight loss, and women's health. Further, the company owns and operates Perform, a sports medicine, physiotherapy, and rehabilitation brand; and offers MRI, CT, and ultrasound scanning, as well as X-ray scanning, pathology, and consulting services. It offers diagnostics, in-patient, daycase, and out-patient care services through 39 hospitals and eight clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4Y 8EN",
        "website": "http://www.spirehealthcare.com",
        "market_cap": "Small Cap"
    },
    "S4BA.F": {
        "short_name": "F-STAR THERAPEUT.DL-,0001",
        "long_name": "F-star Therapeutics, Inc.",
        "summary": "F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118, is currently being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB22 3AT",
        "website": "http://www.f-star.com",
        "market_cap": "Small Cap"
    },
    "SAR.L": {
        "short_name": "SAREUM HOLDINGS PLC ORD 0.025P",
        "long_name": "Sareum Holdings plc",
        "summary": "Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB22 3FX",
        "website": "http://www.sareum.com",
        "market_cap": "Small Cap"
    },
    "SBI.L": {
        "short_name": "SOURCEBIO INTERNATIONAL PLC ORD",
        "long_name": "Sourcebio International Plc",
        "summary": "Sourcebio International Plc provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom and internationally. The company's services cover histopathology reporting and human tissue testing services; genomics services to pharmaceuticals, biotechnology, life science, and academic markets; stability storage solutions; and COVID-19 antigen PCR testing services. It also manufactures reagents and kits for the blood group serology, blood banking, and tissue banking sectors; and engages in life science research activities, which cover antibodies, clones, cell culture reagents and assays, protein biology, laboratory essentials, and others. Sourcebio International Plc was incorporated in 2016 and is headquartered in Nottingham, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Nottingham",
        "zipcode": "NG8 6PX",
        "website": "http://www.sourcebioscience.com",
        "market_cap": "Small Cap"
    },
    "SBTX.L": {
        "short_name": "SKINBIOTHERAPEUTICS PLC ORD 1P",
        "long_name": "SkinBioTherapeutics Plc",
        "summary": "SkinBioTherapeutics plc, a life science company, engages in the research and development of lysates derived from the human microbiome on skin. The company focuses on the development of SkinBiotix technology for use in cosmetic, infection control, and eczema applications. It has an agreement with Croda International Plc for the design and manufacture of a new active cosmetic skincare ingredient based on its SkinBiotix skin microbiome technology; and a research programme with the University of Manchester to investigate and develop microbiome formulations. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Macclesfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Macclesfield",
        "zipcode": "SK11 7QJ",
        "website": "http://www.skinbiotherapeutics.com",
        "market_cap": "Small Cap"
    },
    "SCLP.L": {
        "short_name": "SCANCELL HOLDINGS PLC ORD 0.1P",
        "long_name": "Scancell Holdings plc",
        "summary": "Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GP",
        "website": "http://www.scancell.co.uk",
        "market_cap": "Small Cap"
    },
    "SCP.F": {
        "short_name": "SCANCELL HLDGS  LS -,001",
        "long_name": "Scancell Holdings plc",
        "summary": "Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GP",
        "website": "http://www.scancell.co.uk",
        "market_cap": "Small Cap"
    },
    "SENS.L": {
        "short_name": "SENSYNE HEALTH PLC ORD 10P",
        "long_name": "Sensyne Health plc",
        "summary": "Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for coronavirus self-monitoring; DBm-Health, which helps individuals monitor their blood glucose levels and share their readings with health care professionals; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include SEND, an early warning system for monitoring patient vital signs in hospital; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. Sensyne Health has strategic research alliance with Bayer to develop new treatments using clinical artificial intelligence; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Milton Keynes University Hospital NHS Foundation Trust to enable the ethical application of clinical artificial intelligence research to improve patient care and research into new medicines; collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Hampshire Hospitals NHS Foundation Trust. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GE",
        "website": "http://www.sensynehealth.com",
        "market_cap": "Small Cap"
    },
    "SFLM": {
        "short_name": "SFLMAVEN CORP",
        "long_name": "SFLMaven, Inc.",
        "summary": "DNA Dynamics, Inc., through its subsidiaries, develops mobile applications and games for smartphones and tablet devices. It develops and publishes games for Apple iPhone/iPad/iPod touch and Android platforms; and develops video games and applications for mobile devices and handheld consoles. The company develops games across seven platforms, including titles for TV brands and intellectual property holders. DNA Dynamics, Inc. was incorporated in 1981 and is headquartered in Leamington Spa, United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Leamington Spa",
        "zipcode": "CV32 5LW",
        "website": "http://www.dnadynamicsinc.com",
        "market_cap": null
    },
    "SHIEF": {
        "short_name": "SHIELD THERAPEUTICS PLC",
        "long_name": "Shield Therapeutics plc",
        "summary": "Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Gateshead",
        "zipcode": "NE8 3DF",
        "website": "http://www.shieldtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "SLN.L": {
        "short_name": "SILENCE THERAPEUTICS PLC ORD 5P",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W14 8TH",
        "website": "http://www.silence-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "SLN": {
        "short_name": "Silence Therapeutics Plc - Amer",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NCM",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W14 8TH",
        "website": "http://www.silence-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "SLNCF": {
        "short_name": "SILENCE THERAPEUTICS PLC",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W14 8TH",
        "website": "http://www.silence-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "SN.L": {
        "short_name": "SMITH & NEPHEW PLC ORD USD0.20",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Watford",
        "zipcode": "WD18 8YE",
        "website": "http://www.smith-nephew.com",
        "market_cap": "Large Cap"
    },
    "SNG.L": {
        "short_name": "SYNAIRGEN PLC ORD 1P",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Southampton",
        "zipcode": "SO16 6YD",
        "website": "http://www.synairgen.com",
        "market_cap": "Small Cap"
    },
    "SNN": {
        "short_name": "Smith & Nephew SNATS, Inc.",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NYQ",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Watford",
        "zipcode": "WD18 8YE",
        "website": "http://www.smith-nephew.com",
        "market_cap": "Large Cap"
    },
    "SNNUF": {
        "short_name": "SMITH & NEPHEW",
        "long_name": "Smith & Nephew plc",
        "summary": "Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Watford",
        "zipcode": "WD18 8YE",
        "website": "http://www.smith-nephew.com",
        "market_cap": "Large Cap"
    },
    "SPEC.L": {
        "short_name": "INSPECS GROUP PLC ORD 1P",
        "long_name": "Inspecs Group plc",
        "summary": "Inspecs Group PLC designs, produces, sells, markets, and distributes fashion eyewear and original equipment manufacturer products worldwide. It provides a range of prescription optical eyewear under the various brand names and private labels; sunglasses; and safety products under the Caterpillar brand. Inspecs Group PLC offers its products directly to retailers, specialist distributors, and brand partners. The company also sells its products through a network of approximately 30,000 points of sale in 80 countries worldwide. Inspecs Group PLC was founded in 1988 and is headquartered in Bath, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Bath",
        "zipcode": "BA1 3AU",
        "website": "http://inspecs.com",
        "market_cap": "Small Cap"
    },
    "SPI.L": {
        "short_name": "SPIRE HEALTHCARE GROUP PLC ORD ",
        "long_name": "Spire Healthcare Group plc",
        "summary": "Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics in the United Kingdom. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, foreign visa medical exams, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory care, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology care, vascular care, weight loss, and women's health. Further, the company owns and operates Perform, a sports medicine, physiotherapy, and rehabilitation brand; and offers MRI, CT, and ultrasound scanning, as well as X-ray scanning, pathology, and consulting services. It offers diagnostics, in-patient, daycase, and out-patient care services through 39 hospitals and eight clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "EC4Y 8EN",
        "website": "http://www.spirehealthcare.com",
        "market_cap": "Small Cap"
    },
    "STX.L": {
        "short_name": "SHIELD THERAPEUTICS PLC ORD 1.5",
        "long_name": "Shield Therapeutics plc",
        "summary": "Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Gateshead",
        "zipcode": "NE8 3DF",
        "website": "http://www.shieldtherapeutics.com",
        "market_cap": "Small Cap"
    },
    "SUN.L": {
        "short_name": "SURGICAL INNOVATIONS GROUP PLC ",
        "long_name": "Surgical Innovations Group plc",
        "summary": "Surgical Innovations Group plc designs, develops, manufactures, and sells devices for use in minimally invasive surgery (SI) and precision engineering markets in the United Kingdom, Europe, the Asia Pacific, the United States, and internationally. It operates through three segments: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The company's SI Brand segment researches, develops, manufactures, and distributes SI branded minimally invasive devices. This segment also offers YelloPort Elite and YelloPort +plus laparoscopic port access systems; LogiRange resposable laparoscopic instrument systems; FastClamp laparoscopic clamping systems; and QuickRange single use laparoscopic instrumentation. Its OEM segment researches, develops, manufactures, and distributes minimally invasive devices for third party medical device companies through own label or co-branding. This segment also provides design and development solutions for producing a final device; and researches, develops, manufactures, and sells minimally invasive technology products for precision engineering applications. The company's Distribution segment distributes medical products through Elemental Healthcare Ltd. It also designs and manufactures autologous blood products. The company sells its products through independent healthcare distributors, as well as its own label products through OEM relationships. Surgical Innovations Group plc was incorporated in 1988 and is based in Leeds, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Leeds",
        "zipcode": "LS16 6QZ",
        "website": "http://www.sigroupplc.com",
        "market_cap": "Small Cap"
    },
    "SYGGF": {
        "short_name": "SYNAIRGEN",
        "long_name": "Synairgen plc",
        "summary": "Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-\u00c3\u009f), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-\u00c3\u009f that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Southampton",
        "zipcode": "SO16 6YD",
        "website": "http://www.synairgen.com",
        "market_cap": "Small Cap"
    },
    "TILS.L": {
        "short_name": "TIZIANA LIFE SCIENCES PLC ORD 3",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 1NA",
        "website": "http://www.tizianalifesciences.com",
        "market_cap": "Small Cap"
    },
    "TIZAF": {
        "short_name": "TIZIANA LIFE SCIENCES PLC",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 1NA",
        "website": "http://www.tizianalifesciences.com",
        "market_cap": "Small Cap"
    },
    "TLSA": {
        "short_name": "Tiziana Life Sciences plc - Ame",
        "long_name": "Tiziana Life Sciences PLC",
        "summary": "Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1K 1NA",
        "website": "http://www.tizianalifesciences.com",
        "market_cap": "Small Cap"
    },
    "TLY.L": {
        "short_name": "TOTALLY PLC ORD 10P",
        "long_name": "Totally plc",
        "summary": "Totally plc, through its subsidiaries, provides out-of-hospital healthcare services in the United Kingdom and Ireland. It operates through Urgent Care and Other segments. The company offers a range of treatment and advice for musculoskeletal injuries and conditions, such as physiotherapy and podiatry to NHS patients; occupational health and ergonomic services to corporate and private clients. It also provides dermatology and referral management services; urgent care services; and clinical health coaching services to educate patients to self-manage their conditions, such as chronic obstructive pulmonary disease; and hospital insourcing services, as well as IT healthcare solutions; and provision for online health and safety risk assessments. The company was incorporated in 1999 and is based in Derby, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Derby",
        "zipcode": "DE1 3QT",
        "website": "http://www.totallyplc.com",
        "market_cap": "Small Cap"
    },
    "TRX.L": {
        "short_name": "TISSUE REGENIX GROUP PLC ORD 0.",
        "long_name": "Tissue Regenix Group plc",
        "summary": "Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. It operates through BioSurgery, Orthopaedics & Dental, Cardiac, and GBM-V divisions. The company provides dCELL technology, a soft tissue decellularisation process that removes DNA and cellular material to reduce risk of injection; and BioRinse technology, a natural bone filler solution for osteoinductive to stimulate and regenerate native bone growth. In addition, the company provides DermaPure, a decellularised dermal allograft for orthopaedics, trauma, and woundcare; DermaPure Non-Oriented Decellularised allograft dermal tissue for urogynaecology and general surgery; and SurgiPure XD, Decellularised xenograft dermal tissue for the repair of hernias and/or body wall defects. Further, it offers OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix for orthopaedics and spine; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedics, trauma, and spine; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company provides DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; CardioPure product; Matrix OI 100 DBM for spine and non-structural bone-grafting; Matrix OI Strips and Blocks, a cell containment scaffold; AmnioWorks for ophthalmology; and sports medicine products. The company was incorporated in 2006 and is based in Garforth, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Garforth",
        "zipcode": "LS25 2GY",
        "website": "http://www.tissueregenix.com",
        "market_cap": "Small Cap"
    },
    "TSTL.L": {
        "short_name": "TRISTEL PLC ORD 1P",
        "long_name": "Tristel plc",
        "summary": "Tristel plc develops, manufactures, and supplies infection and contamination control, and hygiene products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products under the Tristel brand; surface cleaning and disinfection products used in areas, such as hospitals, rescue vehicles, care homes, hospices, dentists, and GP surgeries under the Cache brand; contamination control products for pharmaceutical and personal care industries under the Crystel brand; and animal health infection prevention and control products under the Anistel brand. Tristel plc was founded in 1993 and is based in Snailwell, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Snailwell",
        "zipcode": "CB8 7NY",
        "website": "http://www.tristel.com",
        "market_cap": "Small Cap"
    },
    "UHS.L": {
        "short_name": "UMUTHI HEALTHCARE SOLUTIONS PLC",
        "long_name": "Umuthi Healthcare Solutions Plc",
        "summary": "Umuthi Healthcare Solutions Plc focuses on the distribution of pharmaceuticals and the provision of medical facilities in remote areas in South Africa. It supplies prescription and other medicines to medical practitioners and health centers. The company was incorporated in 2018 and is based in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1W 8DH",
        "website": null,
        "market_cap": "Small Cap"
    },
    "UKXA.F": {
        "short_name": "TOTALLY PLC  LS -,10",
        "long_name": "Totally plc",
        "summary": "Totally plc, through its subsidiaries, provides out-of-hospital healthcare services in the United Kingdom and Ireland. It operates through Urgent Care and Other segments. The company offers a range of treatment and advice for musculoskeletal injuries and conditions, such as physiotherapy and podiatry to NHS patients; occupational health and ergonomic services to corporate and private clients. It also provides dermatology and referral management services; urgent care services; and clinical health coaching services to educate patients to self-manage their conditions, such as chronic obstructive pulmonary disease; and hospital insourcing services, as well as IT healthcare solutions; and provision for online health and safety risk assessments. The company was incorporated in 1999 and is based in Derby, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Derby",
        "zipcode": "DE1 3QT",
        "website": "http://www.totallyplc.com",
        "market_cap": "Small Cap"
    },
    "V4TA.F": {
        "short_name": "VECTURA GROUP LS -,000271",
        "long_name": "Vectura Group plc",
        "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chippenham",
        "zipcode": "SN14 6FH",
        "website": "http://www.vectura.com",
        "market_cap": "Small Cap"
    },
    "VACC": {
        "short_name": "Vaccitech plc",
        "long_name": "Vaccitech plc",
        "summary": "Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Oxford",
        "zipcode": "OX4 4GE",
        "website": "http://www.vaccitech.co.uk",
        "market_cap": "Small Cap"
    },
    "VAL.L": {
        "short_name": "VALIRX PLC ORD 0.1P",
        "long_name": "ValiRx plc",
        "summary": "ValiRx plc, a biotechnology oncology focused company, engages in developing novel therapeutics and associated biomarkers for cancer in the United Kingdom. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the treatment of women with endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a candidate produced by GeneICE technology platform to modulate BCl2 expression \u00c2\u0096 implicated in cancers. ValiRx plc has collaboration agreement with Oncolytika Limited and Black Cat Bio Limited to develop and evaluate BC201 for patients suffering a hyperimmune response to Coronavirus SARS-CoV2 infection. The company was incorporated in 2000 and is based in Hatfield, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Hatfield",
        "zipcode": "CM22 7BD",
        "website": "http://www.valirx.com",
        "market_cap": "Small Cap"
    },
    "VEC.L": {
        "short_name": "VECTURA GROUP PLC ORD 0.0271P",
        "long_name": "Vectura Group plc",
        "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chippenham",
        "zipcode": "SN14 6FH",
        "website": "http://www.vectura.com",
        "market_cap": "Small Cap"
    },
    "VEGPF": {
        "short_name": "VECTURA GROUP",
        "long_name": "Vectura Group plc",
        "summary": "Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Chippenham",
        "zipcode": "SN14 6FH",
        "website": "http://www.vectura.com",
        "market_cap": "Small Cap"
    },
    "VICA": {
        "short_name": "RAFINA INNOVATIONS INC",
        "long_name": "Rafina Innovations Inc.",
        "summary": "Rafina Innovations Inc. engages in the research, development, commercialization, and marketing of medical technologies. It operates through two segments, Clinics and Technology. The company also operates prosthetics and orthotics, and diabetic foot total rehabilitation clinics in Southern Europe, the Middle East, and North Africa. In addition, it is involved in the research, development, and commercialization of medical devices, methods, and products in the fields of prosthetics, orthotics, rehabilitation, bioengineering, mobility, diabetes, diabetic foot, tissue mechanics, ultrasonics, medical signal processing and analysis, medical technology, orthopedics, and robotic surgery; and licensing of its proprietary technologies. The company was formerly known as HCi Viocare and changed its name to Rafina Innovations Inc. in July 2018. Rafina Innovations Inc. was founded in 2007 and is based in Glasgow, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Glasgow",
        "zipcode": "G51 1HJ",
        "website": "http://rafina-innovations.com",
        "market_cap": "Small Cap"
    },
    "VLG.L": {
        "short_name": "VENTURE LIFE GROUP PLC ORD 0.3P",
        "long_name": "Venture Life Group plc",
        "summary": "Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, dermo-cosmetics, and topical products for the ageing population in the United Kingdom, Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. It operates through Venture Life Brands and Customer Brands segments. The company offers neurology products, including NeuroAge, NeuroAge Sleep, and NeuroAge NRG food supplements to enhance mental alertness, cognitive function, and mental performance in ageing brain; and Original Bioscalin to treat and prevent hair loss, hair thinning, and baldness. It also provides Fungal Nail Solution, which helps to treat and prevent fungal infections; and Fungal Nail Cleanser for the hygiene of hands and feet prone to fungal nail infections under the Myco Clear brand name. In addition, the company offers UltraDEX Original and UltraDEX Sensitive for bad breath; Dently Dual Action, a mouthwash, which lifts and removes plaque and bacteria from the teeth and mouth; and Procto-eze for anal irritation, including haemorrhoids condition. Further, it provides women healthcare products comprising vonalei bacterial vaginosis, a refreshing gel; vonalei Vaginal Atrophy, a vaginal cream; vonalei candidiasis, a soothing cream-gel for thrush; and vonalei intimate cleansing foam. Additionally, it offers Cleansing Foam, Cleansing Cream, and Serum under the Rosa calma brand name; and skincare ranges to hydrate, nourish, and recondition the skin, as well as to prevent the lines and wrinkles under the Lubatti Classic and the Lubatti Anti-age brand names. The company sells its products through a network of international partners, retail pharmacies, as well as grocery multiple retailers. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Bracknell",
        "zipcode": "RG12 2XB",
        "website": "http://www.venture-life.com",
        "market_cap": "Small Cap"
    },
    "VRCI.L": {
        "short_name": "VERICI DX PLC ORD GBP0.001",
        "long_name": "Verici Dx plc",
        "summary": "Verici Dx plc engages in developing and commercializing clinical diagnostics kidney transplant tests. The company was incorporated in 2020 and is based in Penarth, United Kingdom. As of July 10, 2020, Verici Dx plc is a former subsidiary of Renalytix AI plc.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Penarth",
        "zipcode": "CF64 2EZ",
        "website": "http://www.vericidx.com",
        "market_cap": "Small Cap"
    },
    "VRNA": {
        "short_name": "Verona Pharma plc",
        "long_name": "Verona Pharma plc",
        "summary": "Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "SE1 2RE",
        "website": "http://www.veronapharma.com",
        "market_cap": "Small Cap"
    },
    "WRHLF": {
        "short_name": "LOVE HEMP GROUP PLC",
        "long_name": "Love Hemp Group Plc",
        "summary": "Love Hemp Group Plc formerly known as World High Life Limited, is a private equity and venture capital firm specializing in acquisition, early stage and mature companies. It may invest as debt or equity, in either quoted or unquoted securities, and made by direct acquisition of an interest in companies, partnerships or joint ventures, or direct interests in projects, or by way of licensing arrangements. It typically invests in companies operating in the Cannabidiol (CBD) wellness and medicinal cannabis, hemp including the industrial hemp with focus on therapeutic cannabis derivatives including nutraceuticals, dietary supplements and cosmetic products. The firm also seeks to invest in the cultivation of cannabis and hemp, the manufacture and distribution of medicinal cannabis, hemp and CBD products, pharmacology commercialization of medicinal cannabis, hemp and CBD, professional prescription by practitioners and after care as it relates to medicinal cannabis, statistical management, laboratory testing and compliance in respect of medicinal cannabis, hemp and CBD sectors, and the development of CBD within the wellness sector including retail products such as patches, topical ointments, tinctures, beverages, powdered supplements as well as vaping capsules, e-liquids and oils. The firm typically invests in Europe, Canada, Africa and South America, Israel and Asia. The firm will hold investments for the medium to long term, although where opportunities exist for shorter-term investments, it may undertake such investments. The firm typically acquire control in certain situations, although it may also consider acquiring non-controlling positions. The firm seeks to take majority stake. World High Life Plc was founded on 30th January 2019 and is based in London, United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1B 4DE",
        "website": "http://www.worldhighlife.uk",
        "market_cap": "Small Cap"
    },
    "XRP1.F": {
        "short_name": "SILENCE THERAPEUT. LS-,05",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W14 8TH",
        "website": "http://www.silence-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "XRP2.F": {
        "short_name": "SILENCE THERAP. SP.ADR/1",
        "long_name": "Silence Therapeutics plc",
        "summary": "Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W14 8TH",
        "website": "http://www.silence-therapeutics.com",
        "market_cap": "Small Cap"
    },
    "YGEN.L": {
        "short_name": "YOURGENE HEALTH PLC ORD 0.1P",
        "long_name": "Yourgene Health Plc",
        "summary": "Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, Europe, and internationally. The company develops the IONA Test, an in vitro diagnostic non-invasive pre-natal test (NIPT) screening for pregnant women to estimate Down's syndrome and other genetic disorders. The IONA test enables clinical laboratories to perform their own NIPT screening service. It also offers Cystic Fibrosis screening test; genetic disease screening products; and reproductive health products that include polymerase chain reaction -based screening tests for male factor infertility, recurrent pregnancy loss, and thrombosis. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. The company was incorporated in 2000 and is headquartered in Manchester, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Manchester",
        "zipcode": "M13 9NQ",
        "website": "http://www.yourgene-health.com",
        "market_cap": "Small Cap"
    },
    "ZEG.DE": {
        "short_name": "ASTRAZENECA PLC  DL-,25",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "GER",
        "market": "de_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "ZEG.F": {
        "short_name": "ASTRAZENECA PLC  DL-,25",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "ZEGA.F": {
        "short_name": "ASTRAZENECA DL-,25 SP.ADR",
        "long_name": "AstraZeneca PLC",
        "summary": "AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "United Kingdom",
        "state": null,
        "city": "Cambridge",
        "zipcode": "CB2 0AA",
        "website": "http://www.astrazeneca.com",
        "market_cap": "Large Cap"
    },
    "ZOE.L": {
        "short_name": "ZOETIC INTERNATIONAL PLC ORD 1P",
        "long_name": "Zoetic International Plc",
        "summary": "Zoetic International Plc, a vertically integrated CBD company, researches, develops, produces, and sells cannabidiol (CBD) consumer products and other hemp derivatives in the United States and the United Kingdom. The company offers oral CBD tinctures and CBD gummies, as well as softgel, massage oil, and skincare products. Its CBD products are used for pharmaceutical and tobacco replacement applications. The company was formerly known as Highlands Natural Resources plc and changed its name to Zoetic International Plc in September 2019. Zoetic International Plc was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "GBp",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "LSE",
        "market": "gb_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1W 8DH",
        "website": "http://zoeticinternational.com",
        "market_cap": "Small Cap"
    },
    "ZOEIF": {
        "short_name": "ZOETIC INTERNATIONAL PLC",
        "long_name": "Zoetic International Plc",
        "summary": "Zoetic International Plc, a vertically integrated CBD company, researches, develops, produces, and sells cannabidiol (CBD) consumer products and other hemp derivatives in the United States and the United Kingdom. The company offers oral CBD tinctures and CBD gummies, as well as softgel, massage oil, and skincare products. Its CBD products are used for pharmaceutical and tobacco replacement applications. The company was formerly known as Highlands Natural Resources plc and changed its name to Zoetic International Plc in September 2019. Zoetic International Plc was founded in 2014 and is headquartered in London, the United Kingdom.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "United Kingdom",
        "state": null,
        "city": "London",
        "zipcode": "W1W 8DH",
        "website": "http://zoeticinternational.com",
        "market_cap": "Small Cap"
    }
}